CA2513336A1 - Control of gene expression in a non-human eukaryotic cell, tissue or organ - Google Patents

Control of gene expression in a non-human eukaryotic cell, tissue or organ Download PDF

Info

Publication number
CA2513336A1
CA2513336A1 CA002513336A CA2513336A CA2513336A1 CA 2513336 A1 CA2513336 A1 CA 2513336A1 CA 002513336 A CA002513336 A CA 002513336A CA 2513336 A CA2513336 A CA 2513336A CA 2513336 A1 CA2513336 A1 CA 2513336A1
Authority
CA
Canada
Prior art keywords
nucleic acid
plasmid
acid molecule
gene
pvy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002513336A
Other languages
French (fr)
Inventor
Michael Wayne Graham
Robert Norman Rice
Peter Michael Waterhouse
Ming-Bo Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25645735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2513336(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AUPP2499A external-priority patent/AUPP249998A0/en
Priority claimed from AUPP2492A external-priority patent/AUPP249298A0/en
Application filed by Individual filed Critical Individual
Publication of CA2513336A1 publication Critical patent/CA2513336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • C12N15/69Increasing the copy number of the vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8283Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for virus resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/127RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • C12N2330/51Specially adapted vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/15Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/38Vector systems having a special element relevant for transcription being a stuffer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/42Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/55Vector systems having a special element relevant for transcription from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron

Abstract

The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. Specifically, the invention provides an isolated nucleic acid molecule comprising two or more copies of a ribonucleotide (RNA) sequence which are about 20-100 nucleotides in length and wherein a first copy is at least 80% identical to the nucleotide sequence of a target gene or a region thereof, and at least a second copy is 80% identical to a nucleotide sequence complementary to the target gene or the region thereof, wherein said nucleic acid molecule is capable of reducing expression of the target gene in a mammalian cell when the nucleic acid molecule is introduced into said mammalian cell.

Description

CONTROL OF GENE EXPRESSION BY siRNA
This is a divisional application of Canadian Patent Application Serial No. 2,323,726 filed on March 19, 1999.
FIELD OF THE INVENTION
The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilises recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue, organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto are also provided.
This divisional application is directed to an isolated nucleic acid molecule comprising two or more copies of a ribonucleotide (RNA) sequence which are about 20-100 nucleotides in length and wherein a first copy is at least 80~ identical to the nucleotide sequence of a target gene or a region thereof, and at least a second copy is 800 identical to a nucleotide sequence complementary to the target gene or the region thereof, wherein said nucleic acid molecule is capable of reducing expression of the target gene in a mammalian cell when the nucleic acid molecule is introduced into said mammalian cell. It should be understood that the expression "the invention" and the like encompasses the subject matter of both the parent and this divisional application.

- la -GENERAL
Bibliographic details of the publications referred to in this specification are collected at the end of the description.
As used herein the term "derived from" shall be taken to indicate that a specified integer may be obtained from a particular specified source or species, albeit not necessarily directly from that specified source or species.
Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers but not the exclusion of any other step or element or integer or group of elements or integers.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The WO 99/49029 ~ PCT/AU99/00195 invention also includes alt of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.
The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification 'only.
Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.
Sequence identity numbers (SEQ ID NOS.) containing nucleotide and amino acid sequence information included in this specification are collected after the Abstract and have been prepared using the programme Patentln Version 2Ø Each nucleotide or amino acid sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or amino acid sequence are indicated by information provided in the numeric indicator fields <211 >, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (eg. <400>1, <400>2, etc).
The designation of nucleotide residues referred to herein are those recommended by the IUPAC-IUB~ Biochemical Nomenclature Commission, wherein A represents Adenine, C represents Cytosine, G represents Guanine, T represents thymine, Y
represents a pyrimidine residue, R represents a purine residue, M represents Adeni ne or Cytosine, K represents Guanine or Thymine, S represents Guanine or Cytosine, W
represents Adenine or Thymine, H represents a nucleotide other than Guanine, B
represents a nucleotide other than Adenine; V represents a nucleotide other than Thymine, D represents a nucleotide other than Cytosine and N represents a ny nucleotide residue.

WO 99149029 PCT/AU99l00195 The designation of amino acid residues referred to herein, as recommended by the IUPAC-IUB Biochemical Nomenclature Commission, are listed in Table 1.

S Amino Acid Three-letter code One-letter code Alanine Ala A

Arginine Arg R

Asparagine Asn N

Aspartic acid Asp D

Cysteine Cys C

Glutamine Gln Q

Glutamic acid Glu E

Glycine Gly G

IS Histidine His H

Isoleucine Ile I

Leucine Leu L

Lysine Lys K

Methionine Met M

Phenylalanine Phe F

Proline Pro P

Serine Ser S

Threonine Thr T

Tryptophan Trp W

2S Tyrosine Tyr Y

Valine Val V

Aspartate/AsparagineBaa B

Glutamate/Glutamine Zaa Z

Any amino acid Xaa X

r CA 02513336 1999-03-19 BACKGROUND TO THE INVENTION
Controlling metabolic pathways in eukaryotic organisms is desirable for the purposes of producing novel traits therein or introducing novel traits into a particular cell, tissue or organ of said organism. Whilst recombinant DNA technology has provided significant progress in an understanding of the mechanisms regulating eukaryotic gene expression, much less progress has been made in the actual manipulation of gene expression to produce novel traits. Moreover, there are only limited means by which human intervention may lead to a modulation of the level of eukaryotic gene expression_ IO
One approach to repressing, delaying or otherwise reducing gene expression utilise a mRNA molecule which is transcribed from the complemeritary strand of a nuclear gene to that which is normally transcribed and capable of being translated info a polypeptide. Although the precise mechanism involved in this approach is not established, it has been postulated that a double-stranded mRNA may form by base pairing between the complementary nucleotide sequences, to produce a complex which is translated at tow efficiency and/or degraded by intracellular ribonuclease enzymes prior to being translated.
Alternatively, the expression of an endogenous gene in a cell, tissue or organ may be suppressed when one or more copies of said gene, or one or more copies of a substantially similar gene are introduced into the cell. Whilst the mechanism involved in this phenomenon has not been established and appears to be involve mechanistically heterogeneous processes. For example, this approach has been postulated to involve transcriptional repression, in which case somatically-heritable repressed states of chromatin are formed or alternatively, a post-transcriptional silencing wherein transcription initiation occurs normally but the RNA
products of the co-suppressed genes are subsequently eliminated.
The efficiency of both of these approaches in targeting the expression of specific !fir CA 02513336 1999-03-19 genes is very low and highly variable results are usually obtained.
Inconsistent results are obtained using different regions of genes, for example 5'- untranslated regions, 3'-untranslated regions, coding regions or intron sequences to target gene expression.
Accordingly, there currently exists no consensus as to the nature of genetic sequences which provide the most efficient means for repressing, delaying or otherwise reducing gene expression using existing technologies. Moreover, such a high degree of variation exists between generations such that it is not possible to predict the level of repression of a specific gene in the progeny of an organism in which gene expression was markedly modifred.
Recently, Dorer and Henikoff (1994) demonstrated the silencing of tandemly repeated gene copies in the Drosophila genome and the transcriptional repression of dispersed Drosophila Adh genes by Polycomb genes (i.e. the Pc-G system; Pal-Bhadra et at, 1997). However, such silencing of tandemly repeated gene copies is of little utility in an attempt to manipulate gene expression in an animal cell by recombinant means, wherein the sequences capable of targeting the expression of a particular gene are introduced at dispersed locations in the genome, absent the combination of this approach with gene-targeting technology. Whilst theoretically possible, such combinations would be expected to work at only low-efficiency, based upon the low efficiency of gene-targeting approaches used in isolation and further, would require complicated vector systems. Additionally, the utilisation of transcriptional repression, such as the Drosophila Pc-G system, would appear to require some knowledge of the regulatory mechanisms capable of modulating the expression of any specific target gene and, as a consequence, would be difficult to implement in practice as a general technology for repressing, delaying or reducing gene expression in animal cells.
The poor understanding of the mechanisms involved in these phenomena has meant that there have been few improvements in technologies for modulating the level of gene expression , in particular technologies for delaying, repressing or otherwise reducing the expression of specific genes using recombinant DNA technology.
Furthermore, as a consequence of the unpredictability of these approaches, there is currently no commercially-viable means for modulating the level of expression of a specific gene in a eukaryotic or prokaryotic organism.
Thus; there exists a need for improved methods of modulating gene expression, in particular repressing, delaying or otherwise reducing gene expression in animal cells for the purpose of introducing novel phenotypic traits thereto. In particular, these methods should provide genera! means for phenotypic modification, without the necessity for performing concomitant gene-targeting approaches.
SUMMARY OF THE INVENTION
The invention is based in part on the surprising discovery by the inventors that cells which exhibit one or more desired traits can be produced and selected from transformed cells comprising a nucleic acid molecule operably linked to a promoter, wherein the transcription product of the nucleic acid molecule comprises a nucleotide sequence which is substantially identical to the nucleotide sequence of a transcript of an endogenous or non-endogenous target gene, the expression of which is intended to be modulated. The transformed cells are regenerated into whole tissues, organs or organisms capable of exhibiting novel traits, in particular virus resistance and modified expression of endogenous genes.
Accordingly, one aspect of the present invention provides a method of modulating the expression of a target gene in an animal cell, tissue or organ, said method at least comprising the step of introducing to said cell, tissue or organ one or more dispersed nucleic acid molecules or foreign nucleic acid molecules comprising multiple copies of a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a region thereof or complementary thereto for a time and under conditions sufficient for translation of the mRNA product of said target gene to be modified, subject to the proviso that the transcription of said mRNA product is not exclusively repressed or reduced.
,~' , i:~_.1~-._. /~' fr" n. : ..\

- 6a -Specifically, the invention is directed to an isolated nucleic acid molecule comprising two or more copies of a ribonucleotide (RNA) sequence which are about 20-100 nucleotides in length and wherein a first copy is at least 80o identical to the nucleotide sequence of a target gene or a region thereof, and at least a second copy is 80%
identical to a nucleotide sequence complementary to the target gene or the region thereof, wherein said nucleic acid molecule is capable of reducing expression of the target gene in a mammalian cell when the nucleic acid molecule is introduced into said mammalian cell.

.s _7_ Ire a particularly preferred embodiment, the dispersed nucleic acid molecules or foreign nucleic acid molecules comprises a nucleotide sequence which encodes multiple copies of an mRNA molecule which is substantially identical to the nucleotide .. sequence of the mRNA product of the target gene. More preferably, the multiple copies of the target molecule are tandem direct repeat sequences.
In a more particularly preferred embodiment, the dispersed nucleic acid molecule or foreign nucleic acid molecule is in an expressible form. such that it is at least capable of being transcribed to produce mRNA.
The target gene may be a gene which is endogenous to the animal cell or alternatively, a foreign gene such as a viral or foreign genetic sequence, amongst others.
Preferably, the target gene is a viral genetic sequence.
IS The invention is particularly useful in the modulation of eukaryotic gene expression, in particular the modulation of human or animal gene expression and even more particularly in the modulation of expression of genes derived from vertebrate and invertebrate animals, such as insects, aquatic animals leg. fish, shellfish, molluscs, crustaceans such as crabs, lobsters and prawns, avian animals and mammals, amongst others).
A variety of traits are selectable with appropriate procedures and sufficient numbers of transformed cells. Such traits include, but are not limited to, visible traits, disease-resistance traits, and pathogen-resistance traits. The modulatory effect is applicable to a variety of genes expressed in plants and animals including, for example, endogenous genes responsible for cellular metabolism or cellular transformation, including oncogenes, transcription factors and other genes which encode polypeptides involved in cellular metabolism.
For example, an alteration in the pigment production in mice can be engineered by _g-targeting the expression of the tyrosinase gene therein. This provides a novel phenotype of albinism in black mice. By targeting genes required for virus replication in a plant cell or an animal cell, a genetic construct which comprises multiple copies of nucleotide sequence encoding a viral repiicase, polymerise, coat protein or uncoating gene, or protease protein, may be introduced into a cell where it is expressed, to confer immunity against the virus upon the cell.
In performance of the present invention, the dispersed nucleic acid molecule or foreign nucleic acid molecule will generally comprise a nucleotide sequence having greater 14 than about 85% identity to the target gene sequence, however, a higher homology might produce a more effective modulation of expression of the target gene sequence.
Substantially greater homology, or more than about 90% is preferred, and even more preferably about 95% to absolute identity is desirable.
The introduced dispersed nucleic acid molecule or foreign nucleic acid molecule sequence, needing Less than absolute homology, also need not be full length, relative to either the primary transcription product or fully processed mRNA of the target gene.
A higher homology in a shorter than full length sequence compensates for a longer less homologous sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and homology of non-coding segments will be equally effective. Normally, a sequence of greater than 20-100 nucleotides should be used, though a sequence of greater than about 200-300 nucleotides would be preferred, and a sequence of greater than 500-1000 nucleotides would be especially preferred depending on the size of the target gene.
A second aspect of the present invention provides a synthetic gene which is capable of modifying target gene expression in a cell, tissue or organ of a prokaryotic or eukaryotic organism which is transfected or transformed therewith, wherein said synthetic gene at feast comprises a dispersed nucleic acid molecular foreign nucleic acid molecule comprising multiple copies of a nucleotide sequence which is ,' CA 02513336 1999-03-19 WO 99/49029 PCTlAU99/00195 substantially identical to the nucleotide sequence of said target gene or a derivative thereof or a complementary sequence thereto placed operably under the control of a promoter sequence which is operable in said cell, tissue or organ:
A third aspect of the invention provides a synthetic gene which is capable of modifying the expression of a target gene in a cell, tissue or organ of a prokaryotic or eukaryotic organism which is transfected or transformed therewith, wherein said synthetic gene at least comprises multiple structural gene sequences, wherein each of said structural gene sequences comprises a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a derivative thereof or a complementary sequence thereto and wherein said multiple structural gene sequences are placed operably under the control of a single promoter sequence which is operable in said cell, tissue or organ.
A fourth aspect of the present invention provides a synthetic gene which is capable of modifying the expression of a target gene in a cell, tissue or organ of a prokaryote or eukaryote which is transfected or transformed therewith wherein said synthetic gene at least comprises multiple structural gene sequences wherein each of said structural gene sequences is placed operably under the control of a promoter sequence which is operable in said cell, tissue or organ and wherein each of said structural gene sequences comprises a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a derivative (hereof or a complementary sequence thereto.
A fifth aspect of the present invention provides a genetic construct which is capable of modifying the expression of an endogenous gene or target gene in a transformed or transfected cell, tissue or organ wherein said genetic construct at least comprises the synthetic gene of the invention and one or more origins of replication and/or selectable marker gene sequences.

- IO-in order to observe many novel traits in multicellular organisms such as plants and animals, in particular those which are tissue-specific or organ-specific or developmentally-regulated, regeneration of a transformed cell carrying the synthetic genes and genetic constructs described herein into a whole organism will be required.
Those skilled in the art will be aware that this means growing a whole organism from a transformed plant cell or animal cell, a group of such cells, a tissue or organ.
Standard methods for the regeneration of certain plants and animals from isolated cells and tissues are known to those skilled in the art.
I O Accordingly, a sixth aspect of the invention provides a cell, tissue, organ or organism comprising the synthetic genes and genetic constructs described herein.
BRIEF DESCRIPTION OF THE DRAWINGS
IS Figure 1 is a diagrammatic representation of the plasmid pEGFP-N1 MGS.
Figure 2 is a diagrammatic representation of the plasmid pCMV.cass.
Figure 3 is a diagrammatic representation of the plasmid pCMV.SV40L.cass.
Figure 4 is a diagrammatic representation of the plasmid pCMV.SV40LR.cass.
Figure 5 is a diagrammatic representation of the plasmid pCR.Bg(-GFP-Bam.
Figure 6 is a diagrammatic representation of the plasmid pBSll(SK+).EGFP.
Figure 7 is a diagrammatic representation of the plasmid pCMV.EGFP.
Figure 8 is a diagrammatic representation of the plasmid pCR.SV40L.

. _ 11 -Figure 9 is a diagrammatic representation of the plasmid pCR.BEV.l.
Figure 10 is a diagrammatic representation of the plasmid pCR.BEV.2. , Figure 11 is a diagrammatic representation of the plasmid pCR.BEV.3.
Figure 12 is a diagrammatic representation of the plasmid pCMV.EGFP.BEV2.
Figure 13 is a diagrammatic representation of the plasmid pCMV.BEV.2.
Figure 14 is a diagrammatic representation of the plasmid pCMV.BEV.3.
Figure 15 is a diagrammatic representation of the plasmid pCMV.VEB.
Figure 16 is a diagrammatic representation of the plasmid pCMV . BEV.. GFP .
Figure 17 is a diagrammatic representation of the plasmid pCMV.BEV.SV40LØ
Figure 18 is a diagrammatic representation of the plasmid pCMVØSV40L.BEV. _ _ Figure 19 is a diagrammatic representation of the plasmid pCMVØSV40L.VEB.
Figure 20 is a diagrammatic representation of the plasmid pCMV.BEVx2.' Figure 21 is a diagrammatic representation of the plasmid pCMV.BEVx3.

~2 6 - 3 ( S ~ CA 02513336 1999-03-19 Figure 22 is a diagrammatic representation of the plasmid pCMV.BEVx4.
Figure 23 is a diagrammatic representation of the plasmid pCMV.BEV.SV40L.BEV.
Figure 24 is a diagrammatic representation of the plasmid pCMV.BEV.SV40L.VEB.
Figure 25. is a diagrammatic representation of the plasmid pCMV.BEV.GFP.VEB.
Figure 26 is a diagrammatic representation of the plasmid pCMV.EGFP.BEV2.PFG.
Figure 27 is a diagrammatic representation of the plasmid pCMV.BEV.SV40LR.
Figure 28 is a diagrammatic representation of the plasmid pCDNA3.Galt.
Figure 29 is a diagrammatic representation of the plasmid pCMV.GaIt.
Figure 30 is a diagrammatic representation of the plasmid pCMV.EGFP.Galt.
Figure 3.1 is a diagrammatic representation of the plasmid pCMV.GaIt.GFP.
Figure 32 is a diagrammatic representation of the plasmid pCMV.Galt.SV40LØ
Figure 33 is a diagrammatic representation of the plasmid pCMVØSV40L.t1aG.
Figure 34 is a diagrammatic representation of the plasmid pCMVØSV40L.Galt.

~2~ 6 -3 ~ S ~ CA 02513336 1999-03-19 ' ' - 13 -Figure 35 is a diagrammatic representation of the plasmid pCMV.Galtx2.
Figure 36 is a diagrammatic representation of the plasmid pCMV.Galtx4.
Figure 37 is a diagrammatic representation of the plasmid pCMV.GaIt.SV40L.Galt.
Figure 38 is a diagrammatic representation of the plasmid pCMV.GaIt.SV40L.t1aG.
Figure 39 is a diagrammatic representation of the plasmid pCMV.GaIt.GFP.tIaG.
Figure 40 is a diagrammatic representation of the plasmid pCMV.EGFP.Galt.PFG.
Figure 41 is a diagrammatic representation of the plasmid pCMV.GaIt.SV40LR.
Figure 42 is a diagrammatic representation of the plasmid pART7.
Figure 43 is a diagrammatic representation of the plasmid pAR.T7.35S.SCBV.cass.
Figure 44 is a diagrammatic representation of the plasmid 2o pBC.PVY.
Figure 45 is a diagrammatic representation of the plasmid pSP72.PVY.
Figure 46 is a diagrammatic representation of the plasmid CIapBC.PVY.
Figure 47 is a diagrammatic representation of the plasmid pBC.PVYx2.

~~6-3 (S) Figure 48 is a diagrammatic representation of the plasmid pSP72.PVYx2.
Figure 49 is a diagrammatic representation of the plasmid pBC.PVYx3.
Figure 50 is a diagrammatic representation of the plasmid pBC.PVYx4.
Figure 51 is a diagrammatic representation of the plasmid pBC.PVY.LNYV.
Figure 52 is a diagrammatic representation of the plasmid pBC.PVY.LNYV.PVY.
Figure 53 is a diagrammatic representation of the plasmid pBC.PVY.LNYV.YVP~.-Figure 54 is a diagrammatic representation of the plasmid pBC.PVY.LNYV.YVP:
Figure 55 is a diagrammatic representation of the plasmid pART7.PVY.
Figure 56 is a diagrammatic representation of the plasmid pART7.35S.PVY.SCBV.O.
Figure 57 is a diagrammatic representation of the plasmid pART7.35S.O.SCBV.PVY.
Figure 58 is a diagrammatic representation of the plasmid pART7.35S.O.SCBV.YVP.
Figure 59 is a diagrammatic representation of the plasmid pART7.PVYx2.
Figure 60 is a diagrammatic representation of the plasmid pART7.PVYx3.

~~6-3 (S) - 14a -Figure 61 is a diagrammatic representation of the plasmid pART7.PVYx4.
Figure 62 is a diagrammatic representation of the plasmid pART7.PVY.LNYV.PVY.
Figure 63 is a diagrammatic representation of the plasmid pART7.PVY.LNYV.YVPO.
Figure 64 is a diagrammatic representation of the plasmid pART7.PVY.LNYV.YVP.
Figure 65 is a diagrammatic representation of the plasmid pART7.35S.PVY.SCBV.YVP.
Figure 66 is a diagrammatic representation of the plasmid pART7.35S.PVYx3.SCBV.YVPx3.
Figure 67 is a diagrammatic representation of the plasmid pART7.PVYx3.LNYV.YVPx3.
Figure 68 is a diagrammatic representation of the plasmid pART7..PVYMULTI.

' WO 99/49029 PCT/AU99/00195 DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a method of modulating the expression of a target gene in a cell, tissue or organ, said method at least comprising the step of introducing to said cell, tissue or organ one or more dispersed nucleic acid molecules or foreign nucleic acid molecules comprising multiple copies of a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a region thereof or complementary thereto for a time and under conditions sufficient for translation of the mRNA product of said target gene to be modified, subject to the proviso that the transcription of said mRNA product is not exclusively repressed or red uced.
By "multiple copies" is meant that two or more copies of the target gene are presented in close physical connection or juxtaposed, in the same or different orientation, on the same nucleic acid molecule, optionally separated by a stuffer fragment or intergenic region to facilitate secondary structure formation between each repeat where this is required. The stuffer fragment may comprise any combination of nucleotide or amino acid residues, carbohydrate molecules or oligosaccharide molecules or carbon atoms or a homologue, analogue or derivative thereof which is capable of being linked covalently to a nucleic acid molecule.
Preferably, embodiment, the stuffer fragment comprises a sequence of nucleotides or a homologue, analogue or derivative thereof.
More preferably, the stuffer fragment comprises a sequence of nucleotides of at least about 10-50 nucleotides in length, even more preferably at least about 50-100 nucleotides in length and still more preferably at least about 100-500 nucleotides in length.
Wherein the dispersed or foreign nucleic acid molecule comprises intron/exon splice junction sequences, the stuffer fragment may serve as an intron sequence placed between the 3'-splice site of the structural gene nearer the 5'-end of the gene and the 5'- splice site of the next downstream unit thereof. Alternatively, wherein it is desirable for more than two adjacent nucleotide sequence units of the dispersed foreign nucleic acid molecule to be translated, the stuffer fragment placed there between should not include an in-frame translation stop codon, absent intron/exon splice junction sequences at both ends of the stuffer fragment or the addition of a translation start codon at the 5' end of each unit, as wilt be obvious to those skilled in tile art.
Preferred stuffer fragments are those which encode detectable marker proteins or biologically-active analogues and derivatives thereof, for example luciferase, ~i-galacturonase, ~i-galactosidase, chloramphenicol acetyltransferase or green fluorescent protein, amongst others. Additional stuffer fragments are not excluded.
IS According to this embodiment, the detectable marker or an analogue or derivative thereof serves to indicate the expression of the synthetic gene of the invention in a cel l, tissue or organ by virtue of its ability to confer a specific detectable phenotype thereon, preferably a visually-detectable phenotype.
As used herein, the term "modulating" shall be taken to mean that expression of the target gene is reduced in amplitude and/or the timing of gene expression is delayed and/or the developmental or tissue-specific or cell-specific pattern of target gene expression is altered, compared to the expression of said gene in the absence of the inventive method described herein. _ Whilst not limiting the scope of the invention described herein, the present invention is directed to a modulation of gene expression which comprises the repression, delay or reduction in amplitude of target gene expression in a specified cell, tissue or organ of a eukaryotic organism, in particular a plant such as a monocotyledonous or dicotyledonous plant, or a human or other animal and even more particularly a ' CA 02513336 1999-03-19 vertebrate and invertebrate animal, such as an insect, aquatic animal (eg.
fish, shellfish, mollusc, crustacean such as a crab, lobster or prawn, an avian animal or a mammal, amongst others).
S More preferably, target gene expression is completely inactivated by the dispersed nucleic acid molecules or foreign nucleic acid molecules which has been introduced to the cell, tissue or organ.
Whilst not being bound by any theory or mode of action, the reduced or eliminated expression of the target gene which results from the performance of the invention may be attributed to reduced or delayed translation of the mRNA transcription product of the target gene or attematively, the prevention of translation of said mRNA, as a consequence of sequence-specific degradation of the mRNA transcript of the target gene by an endogenous host cell system.
IS
It is particularly preferred that, for optimum results, sequence-specific degradation of the mRNA transcript of the target gene occurs either prior to the time or stage when the mRNA transcript of the target gene would normally be translated or alternatively, at the same time as the mRNA transcript of the target gene would normally be translated. Accordingly, the selection of an appropriate promoter sequence to regulate expression of the introduced dispersed nucleic acid molecule or foreign nucleic acid molecule is an important consideration to optimum performance of the invention. For this reason, strong constitutive promoters or inducible promoter systems are especially preferred for use in regulating expression of the introduced dispersed nucleic acid molecules or foreign nucleic acid molecules.
The present invention clearly encompasses reduced expression wherein reduced expression of the target gene is effected by lowered transcription, subject to the proviso that a reduction in transcription is not the sole mechanism by which this occurs and said reduction in transcription is at least accompanied by reduced translation of ' WO 99/4909 PCT/AU99/00195 -I8_ the steady-state mRNA pool.
The target gene may be a genetic sequence which is endogenous to the animal cell or alternatively, a non-endogenous genetic sequence, such as a genetic sequence which is derived from a virus or other foreign pathogenic organism and is capable of entering a cell and using the cell's machinery following infection.
Wherein the target gene is a non-endogenous genetic sequence to the animal cell, it is desirable that the target gene encodes a function which is essential for replication or reproduction of the viral or other pathogen. In such embodiments, the present invention is particularly useful in the prophylactic and therapeutic treatment of viral infection of an animal cell or for conferring or stimulating resistance against said pathogen.
IS Preferably, the target gene comprises one or more nucleotide sequences of a viral pathogen of a plant or an animal cell, tissue or organ.
For example, in the case of animals and humans, the viral pathogen may be a retrovirus, for example a lentivirus such as the immunodefrciency viruses, a single-stranded (+) RNA virus such as bovine enterovirus (BEV) or Smbis alphavirus.
Alternatively, the target gene can comprise one or more nucleotide sequences of a viral pathogen of an animal cell, tissue or organ, such as but not limited to a double-stranded DNA virus such as bovine herpes virus or herpes simplex virus I (HSV
1), amongst others.
In the case of plants, the virus pathogen is preferably a potyvirus, caulimovirus, badnavirus, geminiyirus, reovirus, rhabdovirus, bunyavirus, tospovirus, tenuivirus, tombusvirus, luteovirus, sobemovirus, bromovirus, cucomovirus, ilavirus, alfamovirus, tobamovirus, tobravirus, potexvirus and ctostrovirus, such as but not limited to CaMV, SCSV, PVX, PVY, PLRV, and TMV, amongst others.

~ WO 99/49029 PCT/AU99/00195 With particular regard to viral pathogens, those skilled in the art are aware that virus encoded functions may be complemented in traps by polypeptides encoded by the host cell. For example, the replication of the bovine herpes virus genome in the host cell may be facilitated by host cell DNA polymerases which are capable of S complementing an inactivated viral DNA polymerase gene.
Accordingly, wherein the target gene is a non-endogenous genetic sequence to the animal cell, a further alternative embodiment of the invention provides for the target gene to encode a viral or foreign polypeptide which is not capable of being complemented by a host cell function, such as a virus-specific genetic sequence.
Exemplary target genes according to this embodiment of the invention include, but are not limited to genes which encode virus coat proteins, uncoating proteins and RNA-dependent DNA polymerases and RNA-dependent RNA polymerases, amongst others.
IS In a particularly preferred embodiment of the present invention, the target gene is the BEV RNA-dependent RNA polymerase gene or a homologue, analogue or derivative thereof or PVY Nia protease-encoding sequences.
The cell in which expression of the target gene is modified may be any cell which is derived from a multicellular plant or animal, including cell and tissue cultures thereof.
Preferably; the animal cell is derived from an insect, reptile, amphibian, bird, human or other mammal. Exemplary animal cells include embryonic stem cells, cultured skin fibroblasts, neuronal cells, somatic cells, haematopoietic stem cells, T-cells and immortalised cell lines such as COS, VERO, HeLa, mouse C127, Chinese hamster ovary (CHO), WI-38, baby hamster kidney (BHK) or MDBK cell lines, amongst others_ Such cells and cell fines are readily available to those skilled in the art.
Accordingly, the tissue or organ in which expression of the target gene is modified may be any tissue or organ comprising such animal cells.
Preferably the plant cell is derived from a monocotyledonous or dicotyledonous plant species or a cell line derived therefrom.
As used herein, the term "dispersed nucleic acid molecule" shall be taken to refer to a nucleic acid molecule which comprises one or more multiple copies, preferably tandem direct repeats, of a nucleotide sequence which is substantially identical or complementary to the nucleotide sequence of a gene which originates from the cell, tissue or organ into which said nucleic acid molecule is introduced, wherein said nucleic acid molecule is non-endogenous in the sense that it is introduced to the cell, tissue or organ of an animal via recombinant means and will generally be present as IO extrachromosomal nucleic acid or alternatively, as integrated chromosomal nucleic acid which is genetically-unlinked to said gene. More particularly, the "dispersed nucleic acid molecule" will comprise chromosomal or extrachromosomat nucleic acid which is unlinked to the target gene against which it is directed in a physical map, by virtue of their not being tandemly-linked or alternatively, occupying a different chromosomal position on the same chromosome or being localised on a different chromosome or present in the cell as an episome, plasmid, cosmid or virus particle.
By "foreign nucleic acid molecule" is meant an isolated nucleic acid molecule which has one or more multiple copies, -preferably tandem direct repeats, of a nucleotide sequence which originates from the genetic sequence of an organism which is different from the organism to which the foreign nucleic acid molecule is introduced.
This definition encompasses ,a nucleic acid molecule which originates from a different individual of the same lowest taxonomic grouping (i_e. the same population) as the taxonomic grouping to which said nucleic acid molecule is introduced, as well as a nucleic acid molecule which originates from a different individual of a different taxonomic grouping as the taxonomic grouping to which said nucleic acid molecule is introduced, such as a gene derived from a viral pathogen.
Accordingly, a target gene against which a foreign nucleic acid molecule acts in the performance of the invention may be a nucleic acid molecule which has been ' CA 02513336 1999-03-19 ~ WO 99/49029 PCT/AU99/00195.

introduced from one organism to another organism using transformation or introgression technologies. Exemplary target genes according to this embodiment of the invention include the green fluorescent protein-encoding gene derived from the jellyfish Aequoria victoria (Prasher et a/.,1992; International Patent Publication No. WO
95/07463), tyrosinase genes and in particular the murine tyrosinase gene (Kwon et a1.,1988), the Escherichia coli lacl gene which is capable of encoding a polypeptide repressor of the~lacZ gene, the porcine a-1,3-galactosyltransferase gene (NCB/
Accession No. L36535) exemplified herein, and the PVY and BEV structural genes exemplified herein or a homologue, analogue or derivative of said genes or a complementary nucleotide sequence thereto.
The present invention is further useful for simultaneously targeting the expression of several target genes which are co-expressed in a particular cell, for example by using a dispersed nucleic acid molecule or foreign nucleic acid molecule which comprises nucleotide sequences which are substantially identical to each of said co-expressed target genes.
By "substantially identical" is meant that the introduced dispersed or foreign nucleic acid molecule of the invention and the target gene sequence are sufficiently identical at the nucleotide sequence level to permit base-pairing there between under standard intracellular conditions.
Preferably, the nucleotide sequence of each repeat in the dispersed or foreign nucleic acid molecule of the invention and the nucleotide sequence of a part of the target gene sequence are at least about 80-85% identical at the nucleotide sequence level, more preferably at least about 85-90% identical, even more preferably at least about 90-95%
identical and still even more preferably at least about 95-99% or 100%
identical at the nucleotide sequence level.
Notwithstanding that the present invention is not limited by the precise number of . CA 02513336 1999-03-19 repeated sequences in the dispersed nucleic acid molecule or the foreign nucleic acid molecule of the invention, it is to be understood that the present invention requires at least two copies of the target gene sequence to be expressed in the cell.
Preferably, the multiple copies of the target gene sequence are presented in the dispersed nucleic acid molecule or the foreign nucleic acid molecule as tandem inverted repeat sequences and/or tandem direct repeat sequences. Such configurations are exemplified by the "test plasmids" described herein that comprise Galt, BEV or PVY gene regions.
Preferably, the dispersed or foreign nucleic acid molecule which is introduced to the cell, tissue or organ comprises RNA or DNA.
Preferably, the dispersed or foreign nucleic acid molecule further comprises a nucleotide sequence or is complementary to a nucleotide sequence which is capable of encoding an amino acid sequence encoded by the target gene. Even more preferably, the nucleic acrd molecule includes one or more ATG or AUG
translational start codons.
Standard methods may be used to introduce the dispersed nucleic acid molecule or foreign nucleic acid molecule info the cell, tissue or organ for the purposes of modulating the expression of the target gene. For example, the nucleic acid molecule may be introduced as naked DNA or RNA, optionally encapsulated in a liposome, in a virus particle as attenuated virus or associated with a virus coat or a transport protein , or inert carrier such as gold or as a recombinant viral vector or bacterial vector or as a genetic construct, amongst others.
Administration means include injection and oral ingestion (e.g. in medicated food material), amongst others.

~ CA 02513336 1999-03-19 The subject nucleic acid molecules may also be delivered by a live delivery system such as using a bacterial expression system optimised for their expression in bacteria which can be incorporated into gut flora. Alternatively, a viral expression system can be employed. In this regard, one form of viral expression is the administration of a live vector generally by spray, feed or water where an infecting effective amount of the live vector (e.g. virus or bacterium) is provided to the animal. Another form of viral expression system is a non-replicating virus vector which is capable of infecting a cell but not replicating therein. The non-replicating viral vector provides a means of introducing to the human or animal subject genetic material for transient expression therein. The mode of administering such a vector is the same as a live viral vector.
The carriers, excipients and/or diluents utilised in delivering the subject nucleic acid molecules to a host cell should be acceptable for human or veterinary applications.
Such carriers, excipients andlor diluents are well-known to those skilled in the art.
Carriers and/or diluents suitable for veterinary use include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the composition is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
In an alternative embodiment, the invention provides a method of modulating the expression of a target gene in a cell, tissue or organ, said method at least comprising the steps of:
(i) selecting one or more dispersed nucleic acid molecules or foreign nucleic acid molecules which comprise multiple copies of a nucleotide sequence which is substantially identical to the nucleotide sequence of said target gene or a region thereof or which is complementary thereto; and (ii) introducing said dispersed nucleic acid molecules or foreign nucleic acid molecules to said cell, tissue or organ for a time and under conditions sufficient for translation of the mRNA product of said target gene to be modified, subject to the proviso that the transcription of said mRNA product is not exclusively repressed or reduced.
To select appropriate nucleotide sequences for targeting expression of the target gene, several approaches may be employed. In one embodiment, multiple copies of specific regions of characterised genes may be cloned in operable connection with a suitable promoter and assayed for efficacy in reducing target gene expression.
Alternatively, shotgun libraries comprising multiple copies of genetic sequences fnay be produced and assayed for their efficacy in reducing target gene expression. The advantage associated with the latter approach is that it is not necessary to have any prior knowledge of the significance of any particular target gene in specifying an undesirable phenotype in the cell. For example, shotgun libraries comprising virus sub-genomic fragments may be employed and tested directly for their ability to confer virus immunity on the animal host cell, without prior knowledge of the role which any virus genes play in pathogenesis of the host cell.
As used herein, the term "shotgun library" is a set of diverse nucleotide sequences wherein each member of said set is preferably contained within a suitable plasmid, cosmid, bacteriophage or virus vector molecule which is suitable for maintenance and/or replication in a cellular host. The term "shotgun library" includes a representative library, in which the extent of diversify between the -nucleotide sequences is numerous such that all sequences in the genome of the organism from which 'said nucleotide sequences is derived are present in the "set" or alternatively, a limited library in which there is a lesser degree of diversity between said sequences.
The term "shotgun library" further encompasses random nucleotide sequences, wherein the nucleotide sequence comprises viral or cellular genome fragments, amongst others obtained for example by shearing or partial digestion of genomic DNA
using restriction endonucieases, amongst other approaches. A "shotgun library"
further includes cells, virus particles and bacteriophage particles comprising the individual nucleotide sequences of the diverse set.
Preferred shotgun libraries according to this embodiment of the invention are "representative libraries", comprising a set of tandem repeated nucleotide sequences derived from a viral pathogen of a plant or an animal.
In a particularly preferred embodiment of the invention, the shotgun library comprises cells, virus particles or bacteriophage particles comprising a diverse set of tandem-repeated nucleotide sequences which encode a diverse set of amino acid sequences, wherein the member of said diverse set of nucleotide sequences are placed operably under the control of a promoter sequence which is capable of directing the expression of said tandem-repeated nucleotide sequence in the cell.
Accordingly, the nucleotide sequence of each unit in the tandem-repeated sequence may comprise at least about 1 to 200 nucleotides in length. The use of larger fragments, particularly employing randomly sheared nucleic acid derived from viral, plant or animal genomes, is not excluded.
The introduced nucleic acid molecule is preferably in an expressible form.
By "expressible form" is meant that the subject nucleic acid molecule is presented in an arrangement such that it may be expressed in the cell, tissue, organ or whole organism, at least at the transcriptional level (i.e. it is expressed in the animal cell to yield at feast an mRNA product which is optionally translatable or translated to produce a recombinant peptide, oligopeptide or polypeptide molecule).
By way of exemplification, in order to obtain expression of the dispersed nucleic acid molecule or foreign nucleic acid molecule in the cell, tissue or organ of interest, a synthetic gene or a genetic construct comprising said synthetic gene is produced, wherein said synthetic gene comprises a nucleotide sequence as described supra in ~ CA 02513336 1999-03-19 ' WO 99/49029 PCT/AU99/00195 operable connection with a promoter sequence which is capable of regulating expression therein. Thus, the subject nucleic acid molecule will be operably connected to one or more regulatory elements sufficient for eukaryotic transcription to occur.
Accordingly, a further alternative embodiment of the invention provides a method of modulating the expression of a target gene in an animal cell, tissue or organ, said method at least comprising the steps of:
(i) selecting one or more dispersed nucleic acid molecules or foreign nucleic acid molecules which comprise multiple copies, preferably tandem repeats, of a nucleotide sequence which is substantially identical to the nucleotide sequence of .said target gene or a region thereof or which is complementary thereto-, (ii) producing a synthetic gene comprising said dispersed nucleic acid molecules or foreign nucleic acid molecules;
(iii) introducing said synthetic gene to said cell, tissue or organ; and (iv) expressing said synthetic gene in said cell, tissue or organ for a time and under conditions sufficient for translation of the mRNA product of said target gene to be modified, subject to the proviso that the transcription of said mRNA
product is not exclusively repressed or reduced.
Reference herein to a "gene" or "genes" is to be taken in its broadest context and includes: ~ _ (i) a classical genomic gene - consisting of transcriptional and/or translational regulatory sequences and/or a coding region and/or non-translated sequences (i.e.
introns, 5'- and 3'- untranslated sequences); and/or (ii) mRNA or cDNA corresponding to the coding regions (i.e. exons) and 5'- and 3'-untranslated sequences of the gene; and/or (iii) a structural region corresponding to the coding regions (i.e. exons) optionally further comprising untranslated sequences and/or a heterologous promoter sequence which consists of transcriptional and/or translational regulatory regions capable of ' CA 02513336 1999-03-19 conferring expression characteristics on said structural region.
The term "gene" is also used to describe synthetic or fusion molecules encoding all or part of a functional product, in particular a sense or antisense mRNA product or a peptide, oligopeptide or polypeptide or a biologically-active protein.
The term "synthetic gene" refers to a non-naturally occurring gene as hereinbefore defined which preferably comprises at least one or more transcriptional and/or translational regulatory sequences operably linked to a structural gene sequence.
The teen "structural gene" shall be taken to refer to a nucleotide sequence which is capable of being transmitted to produce mRNA and optionally, encodes a peptide, oligopeptide, polypeptide or biologically active protein molecule. Those skilled in the art will be aware that not all mRNA is capable of being translated into a peptide, oligopeptide; polypeptide or protein, for example if the mRNA lacks a functional translation start signal or alternatively, if the mRNA is antisense mRNA. The present invention clearly encompasses synthetic genes comprising nucleotide sequences which are not capable of encoding peptides, oligopeptides, polypeptides or biologically-active proteins. In particular, the present inventors have found That such synthetic genes may be advantageous in modifying target gene expression in cells, tissues or organs of a prokaryotic or eukaryotic organism.
The term "structural gene region" refers to that part of a synthetic gene which comprises a dispersed nucleic acid molecule or foreign nucleic acid molecule as described herein which is expressed in a cell, tissue or organ under the control of a promoter sequence to which it is operably connected. A structural gene region may comprise one or more dispersed nucleic acid molecules and/or foreign nucleic acid molecules operably under the control of a single promoter sequence or multiple promoter sequences. Accordingly, the structural gene region of a synthetic gene may comprise a nucleotide sequence which is capable of encoding an amino acid sequence or is complementary thereto. In this regard, a structural gene region which is used in the performance of the instant invention may also comprise a nucleotide sequence which encodes an animo acid sequence yet lacks a functional translation initiation codon and/or a functional translation stop codon and, as a consequence, does not comprise a complete open reading frame. In the present context, the term "structural gene region" also extends to a non-coding nucleotide sequences, such as 5'- upstream or 3'-downstream sequences of a gene which would not normally be translated in a eukaryotic cell which expresses said gene.
Accordingly, in the context of the present invention, a structural gene region may also comprise a fusion between two or more open reading frames of the same or different genes. In such embodiments, the invention may be used to modulate the expression of one gene, by targeting different non-contiguous regions thereof or alternatively, to simultaneously modulate the expression of several different genes, including different genes of a muttigene family. In the case of a fusion nucleic acid molecule which is non-endogenous to the animal cell and in particular comprises two or more nucleotide sequences derived from a viral pathogen, the fusion may provide the added advantage of conferring simultaneous immunity or protection against several pathogens, by targeting the expression of genes in said several pathogens. Alternatively or in addition, the fusion may provide more effective immunity against any pathogen by targeting the expression of more than one gene of that pathogen.
Particularly preferred structural gene regions according to this aspect of the invention are those which include at least one translatable open reading frame, more preferably further including a translational start codon located at the 5'-end of said open reading frame, albeit not necessarily at the 5'-terminus of said.structural gene region. In this regard, notwithstanding that the structural gene region may comprise at least one translatable open reading frame and/or AUG or ATG translational start codon, the inclusion of such sequences in no way suggests that the present invention requires translation of the introduced nucleic acid molecule to occur in order to modulate the ' CA 02513336 1999-03-19 . WO 99/49029 PCT/AU99/0019~

expression of the target gene. Whilst not being bound by any theory or mode of action, the inclusion of at least one translatable open reading frame and/or translational start codon in the subject nucleic acid molecule may serve to increase stability of the mRNA
transcription product thereof, thereby improving the efficiency of the invention.
The optimum number of structural gene sequences which may be involved in the synthetic gene of the present invention will vary considerably, depending upon the length of each of said structural gene sequences, their orientation and degree of identity to each other. For example, those skilled in the art will be aware of the inherent instability of palindromic nucleotide sequences in vivo and the difficulties associated with constructing long . synthetic genes comprising inverted repeated nucleotide sequences, because of the tendency for such sequences to recombine in vivo. Notwithstanding such difficulties, the optimum number of structural gene sequences to be included in the synthetic genes of the present invention may be IS determined empirically by those skilled in the art, without any undue experimentation and by following standard procedures such as the construction of the synthetic gene of the invention using recombinase-deficient cell lines, reducing the number of repeated sequences to a level which eliminates or minimises recombination events and by keeping the total length of the multiple structural gene sequence to an acceptable limit, preferably no more than 5-10kb, more preferably no more than 2-5kb and even more preferably no more than 0.5-2.Okb in length.
Wherein the structural gene region comprises more than one dispersed nucleic acid molecule or foreign nucleic acid molecule it shall be referred to herein as a "multiple structural gene region" or similar term. The present invention clearly extends to the use of multiple structural gene regions which preferably comprise a direct repeat sequence, inverted repeat sequence or interrupted palindrome sequence of a particular structural gene, dispersed nucleic acid molecule or foreign nucleic acid molecule, or a fragment thereof.

Each dispersed or foreign nucleic acid molecule contained within the multiple structural gene unit of the subject synthetic gene may comprise a nucleotide sequence which is substantially identical to a different target gene in the same organism. Such an arrangement may be of particular utility when the synthetic gene is intended to provide protection against a pathogen in a cell, tissue or organ, in particular a viral pathogen, by modifying the expression of viral target genes. For example, the multiple structural gene may comprise nucleotide sequences (i.e. two or more dispersed or foreign nucleic acid molecules) which are substantially identical to two or more target genes selected from the list comprising DNA polymerise, RNA polymerise, Nia protease, and coat protein or other target gene which is essential for viral infectivity, replication or reproduction. However, it is preferred with this arrangement that the structural gene units are selected such that the target genes to which they are substantially identical are normally expressed at approximately the same time (or later) in an infected cell, tissue or organ as (than) the multiple structural gene of the subject synthetic gene is IS expressed under control of the promoter sequence. This means that the promoter controlling expression of the multiple structural gene will usually be selected to confer expression in the cell, tissue or organ over the entire life cycle of the virus when the viral target genes are expressed at different stages of infection.
As with the individual sequence units of a dispersed or foreign nucleic acid molecule, the individual units of the multiple structural gene may be spatially connected in any orientation relative to each other, for example head-to-head, head-to-tail or tail-to-tail and ail such configurations are within the scope of the invention.
For expression in eukaryotic cells, the synthetic gene generally comprises, in additio n to the nucleic acid molecule of the invention, a promoter and optionally other regulatory sequences designed to facilitate expression of the dispersed nucleic acid molecule or foreign nucleic acid molecule.
Reference herein to a "promoter" is to be taken in its broadest context and includes the transcriptional regulatory sequences of a classical genomic gene, including the TATA
box which is required for accurate transcription initiation, with or without a CCAAT box sequence and additional regulatory elements (i.e. upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue-specific manner. A promoter is usually, but not necessarily, positioned upstream or 5', of a structural gene region, the expression of which it regulates. Furthermore, the regulatory elements comprising a promoter are usually positioned within 2 kb of the start site of transcription of the gene.
In the present context, the term "promoter' is also used to describe a synthetic or fusion molecule, or derivative which confers, activates or enhances expression of a nucleic acid molecule in a cell.
Preferred promoters may contain additional copies of one or more specific regulatory elements, to further enhance expression of the sense molecule and/or to alter the spatial expression and/or temporal expression of said sense molecule. For example, regulatory elements which confer copper inducibility may be placed adjacent to a heterologous promoter sequence driving expression of a sense molecule, thereby conferring copper inducibility on the expression of said molecule.
Placing a dispersed or foreign nucleic acid molecule under the regulatory control of a promoter sequence means positioning the said molecule such that expression is controlled by the promoter sequence.. Promoters are generally positioned 5' (upstream) to the genes that they control. In the construction of heterologous promoter/structural gene combinations it is generally preferred to position the promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting, i.e., the gene from which the promoter is derived. As is known in the art, some variation in this distance can be accommodated without loss of promoter function.
Similarly, the preferred positioning of a regulatory sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting, i.e., the genes from which it is derived. Again, as is known in the art, some variation in this distance can also occur.
Examples of promoters suitable for use in the synthetic genes of the present invention include viral, fungal, bacterial, animal and plant derived promoters capable of functioning in plant, animal, insect, fungal, yeast or bacterial cells. The promoter may regulate the expression of the structural gene component constitutively, or differentially with respect to cell, the tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, or pathogens, or metal ions, amongst others.
Preferably, the promoter is capable of regulating expression of a nucleic acid molecule in a eukaryotic cell, tissue or organ, at least during the period of time over which the target gene is expressed therein and more preferably also immediately preceding the commencement of detectable expression of the target gene in said cell, tissue or organ.
Accordingly, strong constitutive promoters are particularly preferred for the purposes of the present invention or promoters which may be induced by virus infection or the commencement of target gene expression.
Plant-operable and animal-operable promoters are particularly preferred for use in the synthetic genes of the present invention. Examples of preferred promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, fac promoter, SV40 late promoter, SV40 early promoter, RSV LTR
promoter, CMV IE promoter, CaMV 35S promoter, SCSV promoter, SCBV promoter and the Like.
In consideration,of the preferred requirement for high-level expression which coincides with expression of the target gene or precedes expression of the target gene, it is ~2~6-3 (S) CA 02513336 1999-03-19 highly desirable that the promoter sequence is a constitutive strong promoter such as the CMV-IE promoter or the SV40 early promoter sequence, the SV40 late promoter sequence, the CaMV 35S promoter, or the SCBV promoter, amongst others. Those skilled in the art will readily be aware of additional promoter sequences other than those specifically described.
In the present context, the terms "in operable connection with" or "operably under the control" or similar shall be taken to indicate that expression of the structural gene region or multiple structural gene region is under the control of the promoter sequence with which it is spatially connected; in a cell, tissue, organ or whole organism.
In a preferred embodiment of the invention, a structural gene region (i.e. dispersed nucleic acid molecule or foreign nucleic acid molecule) or multiple structural gene region is_placed,operably in connection with a promoter orientation relative to the promoter sequence, such that when it is transcribed an mRNA product is synthesized which, if translated, is capable of encoding a polypeptide product of the target gene or a fragment thereof.
However, the present invention is not~to be limited to the use of such an arrangement and the invention clearly extends to the use of synthetic genes and genetic constructs wherein the structural gene region or multiple structural gene region is placed in the "antisense"
orientation relative to the promoter sequence, such that at least a part of the mRNA transcription product thereof is complementary to the mRNA encoded by the target gene or a fragment thereof.

6 - 3 ~ S ~ CA 02513336 1999-03-19 ' - 33a.-Clearly, as the dispersed nucleic acid molecule, foreign nucleic acid molecule or multiple structural gene region comprises tandem direct and/or inverted repeat sequences of the target gene, all combinations of the above-mentioned configurations are encompassed by the invention.

CA 02513336 '1999-03-19 WO 99/49029 PC'T/AU99/00195 In an alternative embodiment of the invention, the structural gene region or multiple structural gene region is operably connected to both a first promoter sequence and a second promoter sequence, wherein said promoters are located at the distal and proximal ends thereof such that at least one unit of said a structural gene region or multiple structural gene region is placed in the "sense" orientation relative to the first promoter sequence and in the "aritisense" orientation relative to the second promoter sequence_ According to this embodiment, it is also preferred that the first and second promoters be different, to prevent competition there between for cellular transcription factors which bind thereto. The advantage of this arrangement is that the effects of transcription from the first and second promoters in reducing target gene expression in the cell may be compared to determine the optimum orientation for each nucleotide sequence tested.
The synthetic gene preferably contains additional regulatory elements for efficient transcription; for example a transcription termination sequence.
The term "terminator" refers to a DNA sequence at the end of a transcriptional unit which signals termination of transcription. Terminators are 3'-non-translated DNA
sequences containing a polyadenylation signal, which facilitates the addition of polyadenylate sequences to the 3'-end of a primary transcript. Terminators active in plant cells are known and described in the literature. They may be isolated from bacteria, fungi, viruses, animals and/or plants or synthesized de novo.
As with promoter sequences, the terminator may be any terminator sequence which is operable in the cells, tissues or organs in which it is intended to be used.
Examples of terminators particularly suitable for use in the synthetic genes of the present invention include the SV40 polyadenylation signal, the HSV TK
polyadenylation signal, the CYC1 terminator, ADH terminator, SPA terminator, nopaline synthase (NOS) gene terminator of Agrobacferium tumefaciens, the ' CA 02513336 1999-03-19 ~ WO 99/49029 PCT/AU99/00195 terminator of the Cauliflower mosaic virus (CaMV) 35S gene, the zein gene terminator from Zea mays, the Rubisco small subunit gene (SSU) gene terminator sequences, subclover stunt virus (SCSV) gene sequence terminators, any rho-independent E.coli terminator, or the IacZ alpha terminator, amongst others.
In a particularly preferred embodiment, the terminator is the SV40 polyadenylation signal or the HSV TK polyadenylation signal which are operable in animal cells, tissues and. organs, octopine synthase (OCS) or nopaline synthase (NOS) terminator active in plant cells, tissues or organs, or the /acZ alpha terminator which is active in prokaryotic cells.
Those skilled in the art will be aware of additional terminator sequences which may be suitable for, use in performing the invention_ Such sequences may readily be used without any undue experimentation.
Means for introducing (i.e. transfecting or transforming) cells with the synthetic genes described herein or a genetic construct comprising same are well-known to those skilled in the art.
In a further alternative embodiment, a genetic construct is used which comprises two or more structural gene regions or multiple structural gene regions wherein each of said structural gene regions is placed operably under the control of its own promoter sequence. As with other embodiments described herein, the orientation of each structural gene region may be varied to maximise its modulatory effect on target gene 25. expression.
According to this embodiment, the promoters controlling expression of the structural gene unit are preferably different promoter sequences, to reduce competition there between for cellular transcription factors and RNA polymerases. Preferred promoters are selected from those referred to supra.

. ~ CA 02513336 1999-03-19 ' WO 99/49029 PCT/AU99/00195 Those skilled in the art wiU know how to modify the arrangement or configuration of the individual structural genes as described supra to regulate their expression from separate promoter sequences.
S The synthetic genes described supra are capable of being modified further, for example by the inclusion of marker nucleotide sequences encoding a detectable marker enryme or a functional analogue or derivative thereof, to facilitate detection of the synthetic gene in a cell, tissue or organ in which it is expressed.
According to this embodiment, the marker nucleotide sequences will be present in a translatable format and expressed, for example as a fusion pofypeptide with the translation products) of any one or more of the structural genes or alternatively as a non-fusion polypeptide.
Those skilled in the art will be aware of how to produce the synthetic genes described herein and of the requirements for obtaining the expression thereof, when so desired, in a specific cell or cell-type under the conditions desired. In particular, it will be known to those skilled in the art that the genetic manipulations required to perform the present invention may require the propagation of a genetic construct described herein or a derivative thereof in a prokaryotic cell such as an E. toll cell or a plant cell or an animal cell.
The synthetic genes of the present invention may be introduced to a suitable cell, tissue or organ without modification as linear DNA in the form of a genetic construct, optionally contained within a suitable carrier, such as a cell, virus particle or liposome, amongst others. To produce a genetic construct, the synthetic gene of the invention is inserted into a suitable vector or episome molecule, such as a bacteriophage vector, viral vector or a plasmid, cosmid or artificial chromosome vector which is capable of being maintained and/or replicated and/or expressed in the host cell, tissue or organ into which it is subsequently introduced.
Accordingly a further aspect of the invention provides a genetic construct which at WO 99/4909 PCT/AU99/00195.

least comprises the synthetic gene according to any one or more of the embodiments described herein and one or more origins of replication and/or selectable marker gene sequences.
Genetic constructs are particularly suitable for the transformation of a eukaryotic cell to introduce novel genetic traits thereto, in addition to the provision' of resistance characteristics to viral pathogens. Such additional novel traits may be introduced in a separate genetic construct or, alternatively on the same genetic construct which comprises the synthetic genes described herein. Those skilled in the art will recognise the significant advantages, in particular in terms of reduced genetic manipulations and tissue culture requirements and increased cost-effectiveness, of including genetic sequences which encode such additional traits and the synthetic genes described herein in a single genetic construct.
I S Usually, an origin of replication or a selectable marker gene suitable for use in bacteria is physically-separated from those genetic sequences contained in the genetic construct which are intended to be expressed or transferred to a eukaryotic cell, or integrated into the genome of a eukaryotic cell.
In a particularly preferred embodiment, the origin of replication is functional in a bacterial cell and comprises the pUC or the ColE1 origin or alternatively the origin of replication is operable in a eukaryotic cell, tissue and more preferably comprises the 2 micron (2,um) origin of replication or the SV40 origin of reptication.
As used herein, the term "selectable marker gene" includes any gene which confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells which are transfected or transformed with a genetic construct of the invention or a derivative thereof.
Suitable selectable marker genes contemplated herein include the ampicillin-resistance ~~~6,-3 ($) CA 02513336 1999-03-19 gene (Ampr), tetracycline-resistance gene (Tcr), bacterial kanamycin-resistance gene (Kanr), is the zeocin resistance gene (Zeocin is a drug of bleomycin family which is trademark of InVitrogen Corporation), the AURI-C gene which confers resistance to the antibiotic aureobasidin A, phosphinothricin-resistance gene, neomycin phosphotransferase gene (nptlI), hygromycin-resistance gene, ,Q-glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene, green fluorescent protein-encoding gene or the luciferase gene, amongst others.
Preferably, the selectable marker gene is the nptII gene or Kanr gene or green fluorescent protein (GFP)-encoding gene.
Those skilled in the art will be aware of other selectable marker genes useful in the performance of the present invention and the subject invention is not limited by the nature of the selectable marker gene.
The present invention extends to all genetic constructs essentially as described herein, which include further genetic sequences intended for the maintenance and/or replication of said genetic construct in prokaryotes or eukaryotes and/or the integration of said genetic construct or a part thereof into the genome of a eukaryotic cell or organism.
, As with dispersed or foreign nucleic acid molecules, standard methods described supra may be used to introduce synthetic genes and genetic constructs into the cell, tissue or organ for the purposes of modulating the expression of the target gene, for example liposome-mediated transfection or , transformation, transformation of cells with attenuated virus particles or bacterial cells, cell mating, transformation or ~~ 6 - 3 ( S ) CA 02513336 1999-03-19 transfection procedures known to those skilled in the art or described by Ausubel et a1. (1987).
Additional means for introducing recombinant DNA
into plant tissue or cells include, but are not limited to, transformation using CaCl2 and variations thereof, in particular the method described by Hanahan (1983), direct DNA uptake into protoplasts (Krens et al., 1982; Paszkowski et al., 1984), PEG-mediated uptake to protoplasts (Armstrong et al., 1990) microparticle bombardment, electroporation (Fromm et al., 1985), microinjection of DNA (Crossway et al., 1986), microparticle bombardment of tissue explants or cells (Christou et al., 1988; Sanford, 1987), vacuum-infiltration of tissue with nucleic acid, or in the case of plants, T-DNA-mediated transfer from Agrobacterium to the plant tissue as described essentially by An et al. (1985), Herrera-Estrella et al. (1983a, 1983b, 1985).
For microparticle bombardment of cells, a microparticle is propelled into a cell to produce a transformed cell. Any suitable ballistic cell transformation methodology and apparatus can be used in performing the present invention. Exemplary apparatus and procedures are disclosed by Stomp et al. (U.S. Patent No. 5,122,466) and Sanford and Wolf (U. S. Patent No. 4,945,050). When using ballistic transformation procedures, the genetic construct may incorporate a plasmid capable of replicating in.the cell to be transformed.
Examples of microparticles suitable for use in such systems include 1 to 5 um gold spheres. The DNA
construct may be deposited on the microparticle by any suitable technique, such as by precipitation'.
In a further embodiment of the present invention, "~6-3 ~~~ CA 02513336 1999-03-19 - 39a -the synthetic genes and genetic constructs described herein are adapted for integration into the genome of a cell in which it is expressed. Those skilled in the art will be aware that, in order to achieve integration of a genetic sequence or genetic construct into the genome of a host cell, certain additional genetic sequences may be required.
In the case of plants, left and right border sequences from the T-DIVA of the Agrobacterium tumefaciens Ti plasmid will generally be required.
The present invention further extends to an isolated cell, tissue or organ comprising the synthetic gene described herein or a genetic construct comprising same.
The present invention extends further to regenerated tissues, organs and whole organisms derived from said cells, tissues and organs and to propagules and progeny thereof.
For example, plants may be regenerated from transformed plant cells or tissues or organs on hormone-containing media and the regenerated plants may take a variety of forms, such as chimeras of transformed cells arid non-transformed cells;
clonal transformants (e.g., all cells transformed to contain the expression cassette); grafts of transformed and untransformed tissues (e.g., a transformed root stock grafted to an untransformed scion in citrus species). Transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, a first generation (or T1 ) transformed plants may be seifed to give homozygous second generation (or T2) transformed plants, and the T2 plants further propagated through classical breeding techniques.
The present invention is further described with reference to the following non-limiting Examples.

' CA 02513336 1999-03-19 ' WO 99/49029 PCT/AU99100195 Genetic constructs comprising BEV polymerase gene sequences linked to the CMV promoter sequence andlor the SV40L
promoter sequence 1. Commercial Plasm~ds Plasmid pBtuescript II (SK+) Plasmid pBluescript II (SK+) is commercially available from Stratagene and comprises the LacZ promoter sequence and IacZ-alpha transcription terminator, with a multiple cloning site for the insertion of structural gene sequences therein. The p(asmid further comprises the'ColE1 and fl origins of replication and ampicillin-resistance gene.
Plasmid pSVL
Plasmid pSVL is commercially-obtainable from Pharmacia and serves as a source of the SV40 late promoter sequence. The nucleotide sequence of pSVL is also publicly available as GenBank Accession Number 013868.
Plasmid pCR2.1 Plasmid pCR2.1 is commercially available from Invitrogen and comprises the LacZ
promoter sequence and IacZ-a transcription terminator, with a cloning site for the insertion of structural gene sequences there between. Plasmid pCR2.1 is designed to clone nucleic acid fragments by virtue of the A-overhang frequently synthesized by Taq polymerase during the polymerase chain reaction. PCR fragments cloned in this fashion are flanked by two EcoRl sites. The plasmid further comprises the ColE1 and f1 origins of replication and kanamycin-resistance and ampicillin-resistance genes.
Plasmid pEGFP-N1 MCS
Plasmid pEGFP-N1 ~S (Figure 1; Clontech) contains the CMV IE promoter operably connected to an open reading frame encoding a red-shifted variant of wild-type green fluorescent protein (GFP; Prasher et al., 1992; Chalfie ef al., 1994; Inouye and Tsuji, ~2~6-3 (S) CA 02513336 1999-03-19 (1994), which has been optimised for brighter fluorescence.
The specific GFP variant encoded by pEGFP-N1 MCS has been disclosed by Cormack et al. (1996). Plasmid pEGFP-N1 MCS
contains a multiple cloning site comprising BglII and BamHI
sites and many other restriction endonuclease cleavage sites, located between the CMV IE promoter and the GFP open reading frame. Structural genes cloned into the multiple cloning site will be expressed at the transcriptional level if they lack a functional translation start site, however 20 such structural gene sequences will not be expressed at the protein level (i.e. translated). Structural gene sequences inserted into the multiple cloning site which comprise a functional translation start site will be expressed as GFP
fusion polypeptides if they are cloned in-frame with the GFP-encoding sequence. The plasmid further comprises an SV40 polyadenylation signal downstream of the GFP open reading frame to direct proper processing of the 3'-end of mRNA transcribed from the CMV-IE promoter sequence. The plasmid further comprises the SV40 origin of replication functional in animal cells; the neomycin-resistance gene comprising SV40 early promoter (SV40 EP in Figure 1) operably connected to the neomycin/kanamycin-resistance gene derived from Tn5 (Kan/neo in Figure 1) and the HSV thymidine kinase polyadenylation signal (HSV TK poly (A) in Figure 1).
2. Expression cassettes Plasmid pCMV.cass Plasmid pCMV.cass (Figure 2) is an expression cassette for driving expression of a structural gene sequence under control of the CMV-IE promoter sequence.
Plasmid pCMV.cass was derived from pEGFP-N1 MCS by deletion of the GFP open reading frame a follows: Plasmid pEGFP-N1 MCS was digested with PinAI and NotI, blunt-ended using PfuI

~~ 6 - 3 ( S ) CA 02513336 1999-03-19 polymerase and then re-ligated. Structural gene sequences are cloned into pCMV.cass using the multiple cloning site, which is identical to the multiple cloning site of pEGFP-N1 MCS, except it lacks the PinAI site.
Plasmid pCMV.SV40L.cass Plasmid pCMV.SV40L.cass (Figure 3) comprises the synthetic poly A site and the SV40 late promoter sequence from plasmid pCR.SV40L (Figure 48), sub-cloned as a SalI
fragment, into the SalI site of plasmid pCMV.cass (Figure 2), such that the CMV-IE promoter and SV40 late promoter sequences are capable of directing transcription in the same direction. Accordingly, the synthetic poly(A) site at the 5' end of the SV40 promoter sequence is used as a transcription terminator fox structural genes expressed from the CMV IE
promoter in this plasmid, which also provides for the insertion of said structural gene via the multiple cloning site present between the SV40 late promoter (SV40LP) and the synthetic poly(A) site (SV40 pA Figure 5). The multiple cloning sites are located behind the CMV-IE and SV40 late promoters, including BamHI and BglII sites.
Plasmid pCMV.SV40LR.cass Plasmid pCMV.SV40LR.cass (Figure 4) comprises the SV40 late promoter sequence derived from plasmid pCR.SV40L, sub-cloned as a SalI fragment into the SaII site of the plasmid,pCMV'.cass (Figure 2), such that the CMV-IE or the SV40 late promoter may drive transcription of a structural gene or a multiple structural gene unit, in the sense or antisense orientation, as desired. A multiple cloning site is positioned between the opposing CMV-IE and SV40 late promoter sequences in this plasmid to facilitate the introduction of a structural gene sequence. In order for ~6-3 (S~ CA 02513336 1999-03-19 c.
- 43a -expression of a structural gene sequence to occur from this plasmid, it must be introduced with its own transcription termination sequence located at the 3' end, because there are no transcription termination sequences located between the opposing CMV-IE and SV40 late promoter sequences in this plasmid. Preferably, the structural gene sequence or multiple structural gene unit which is to be introduced into pCMV.SV40LR.cass will comprise both a 5' and a 3' polyadenylation signal as follows:
(i) where the structural gene sequence or multiple structural gene unit is to be expressed in the sense orientation from the CMV IE promoter sequence and/or in the antisense orientation from the SV40 late promoter, the 5' polyadenylation signal will be in the antisense orientation and the 3' polyadenylation signal will be in the sense orientation; and (ii) where the structural gene sequence or multiple structural gene unit is .
to be expressed in the antisense orientation from the CMV IE promoter sequence and/or in the sense orientation from the SV40 fate promoter, the 5' polyadenylation signal will be in the sense orientation and the 3' polyadenytation signal will be in the antisense orientation.
Alternatively or in addition, suitably-oriented terminator sequences may be placed at the 5'-end of the CMV and SV40L promoters, as shown in Figure 4.

Alternatively, plasmid pCMV.SV40LR.cass is further modified to produce a derivative plasmid which comprises two polyadenytation signals located between the CMV IE
and SV40 late promoter sequences, in approriate orientations to facilitate expression of any structural gene located therebefinreen in the sense or antisense orientation from either 1S the CMV 1E promoter or the SV40 promoter sequence. The present invention clearly encompasses such derivatives.
Alternatively appropriately oriented terminators could be placed upstream of the CMV
and SV40L promoters such that transcriptional termination could occur after 20 readthrough of each of the two promoters in the antisense orientation.
3. Intermediate Constructs Plasmid pCR.BgI-GFP-Bam Plasmid pCR.BgI-GFP-Bam (Figure 5) comprises an internal region, of the GFP
open .
2S reading frame derived from plasmid pEGFP-N1 MCS (Figure 1) placed operably under the control of the IacZ promoter. To produce this plasmid, a region of the GFP
open ' reading frame was amplified from pEGFP-N1 MCS using the amplification primers Bgt-GFP and GFP-Bam (SEQ ID NOS:1 and 2) and cloned into plasmid pCR2.l. The internal GFP-encoding region in plasmid pCR.Bgl-30 GFP-Bam lacks functional translational start and stop codons.

~~ 0165-1 Plasmid pBSII(SIt+) .EGFP

Plasmid pBSII(SK+).EGFP (Figure 6) comprises the EGFP
open reading frame derived from plasmid pEGFP-N1 MCS (Figure 1) placed operably under the control of the IacZ promoter. To produce this plasmid, the EGFP encoding region of pEGFP-N1 MCS
was excised as a Notl/Xhol fragment and cloned into the Notl/Xhol cloning sites of plasmid pBluescript II (SK+).
Plasmid pCMV.EGFP
Plasmid pCMV.EGFP (Figure 7) is capable of expressing the EGFP structural gene under the control of the CMV-IE
promoter sequence. To produce this plasmid the EGFP sequence from plasmid pBSII(SK+).EGFP was excised as BamHI/SaeI fragment and cloned into the BglII/SacI sites of plasmid pCMV.cass (Figure 2).
Plasmid pCR.SV40L
Plasmid pCR.SV40L (Figure 8) comprises the SV40 late promoter derived from plasmid pSVL (GenBank Accession No.
U13868; Pharmacia), cloned into pCR2.1 (Stratagene). To produce this plasmid, the Sv40 late promoter was amplified using the primers SV40-1 and SV40-2 (SEQ ID NOS:3 and 4) which comprise Sa1 I cloning sites to facilitate sub-cloning of the amplified DNA fragment into pCMV.cass. The primer also contains a synthetic poly (A) site at the 5' end, such that the amplification product comprises the synthetic poly (A) site at the 5' end of the SV40 promoter sequence.

Plasmid pCR.BEV.l The BEV RNA-dependent RNA polymerase coding region was amplified as a 1,385 by DNA fragment from a full-length cDNA clone encoding same, using primers designated BEV-1 and BEV-2(SEQ ID NOS:S and 6), under standard amplification conditions. The amplified DNA contained a 5'-Bgl II
restriction enzyme site, derived from the BEV-1 primer sequence and a 3'BamHI restriction enzyme site, derived from the BEV-2 primer sequence. Additionally, as the BEV-1 primer sequence contains a translation start signal 5'-ATG-3' engineered at positions 15-17, the amplified BEV polymerase structural gene comprises the start site in-frame with BEV polymerase-encoding nucleotide sequences. Thus, the amplified BEV polymerase structural gene comprises the ATG start codon immediately upstream (ie. juxtaposed) to the BEV polymerase-encoding sequence. There is no translation stop codon in the amplified DNA. This plasmid is present as Figure 9.
Plasmid pCR.BEV.2 The complete BEV polymerase coding region was amplified from a full-length cDNA clone encoding same, using primers BEV-1 and HEV-3. Primer BEV-3 comprises a BamHI
restriction enzyme site at positions 5 to 10 inclusive and the complement of a translation stop signal at positions 11 to 13.
As a consequence, an open reading frame comprising a translation start signal and translation stop signal, contained between the Bg1 II and BamHI restriction sites. The amplified fragment was cloned into pCR2.1 (Stratagene) to produce plasmid pCR2.BEV.2 (Figure 10).

-46a-Plasmid pCR.BEV.3 A non-translatable BEV polymerase structural gene was amplified from a full-length BEV polymerase cDNA clone using the amplification primers BEV-3 and BEV-4 (SEQ ID NOS:7 and 8).
Primer BEV-4 comprises a Bg/II site are homologous to nucleotide sequences of the BEV polymerase gene. There is no functional ATG start codon in the amplified DNA product of primers BEV-3 and BEV-4. The HEV polymerase is expressed as part of a polyprotein and, as a consequence, there is no ATG
translation start site in this gene. The amplified DNA was cloned into plasmid pCR2.1 (Stratagene) to yield plasmid pCR.BEV.3 (Figure 11).
Plasmid pCMV.EGFP.BEV2 Plasmid pCMV.EGFP.BEV2 (Figure 12) was produced by cloning the BEV polymerase sequence from pCR.BEV.2 as a BglII/BamHI fragment into the BamHI site of pCMV.EGFP.

~~6-3 (S) 4. Control Plasmids Plasmid pCMV.BEV.2 Plasmid pCMV.BEV.2 (Figure 13) is capable of expressing the entire BEV polymerase open reading frame under the control of CMV-IE promoter sequence. To produce pCMV.BEV.2, the BEV polymerase sequence from pCR.BEV.2 was sub-cloned in the sense orientation as a BglII-to-BamHI
fragment into BglII/BamHI-digested pCMV.cass (Figure 2).
Plasmid pCMV.BEV.3 Plasmid pCMV.BEV.3 (Figure 14) expresses a non-translatable BEV polymerase structural gene in the sense orientation under the control of the CMV-IE promoter sequence. To produce pCMV.BEVnt, the BEV polymerase sequence from pCR.BEV.3 was sub-cloned in the sense orientation as a BglII-to-BamHI fragment into BglII/BamHI-digested pCMV.cass (Figure 2).
Plasmid pCMV.VEB
Plasmid pCMV.VEB (Figure 15) expresses an antisense BEV polymerase mRNA under the control of the CMV-IE promoter sequence. To produce plasmid pCMV.VEB, the BEV
polymerase sequence from pCR.BEV.2 was sub-cloned in the antisense orientation as a BglII-to-BamHI fragment into BgIII/BamHI-digested pCMV.cass (Figure 2).
Plasmid pCMV.BEV.GFP
Plasmid pCMV.BEV.GFP (Figure 16) was constructed by cloning the GFP fragment from pCR.Bgl-GFP-Bam as a BglII/BamHI fragment into BamHI-digested pCMV.BEV.2. This plasmid serves as a control in some experiments and also as an intermediate construct.

~6-3 (S) CA 02513336 1999-03-19 Plasmid pCMV.HEV.SV40L.0 Plasmid pCMV.BEV.SV40L.0 (Figure 17) comprises a translatable BEV polymerase structural gene derived from plasmid pCR.BEV.2 inserted in the sense orientation between the CMV-IE promoter and the SV40 late promoter sequences of plasmid pCMV.SV40L.cass. To produce plasmid pCMV.BEV.SV40L.0, the BEV polymerase structural gene was sub-cloned as a BglII-to-BamHI fragment into BglII-digested pCMV.SV40L.cass DNA.
Plasmid pCMV.O.SV40L.BEV
Plasmid pCMV.O.SV40L.BEV (Figure 18) comprises a translatable BEV polymerase structural gene derived from plasmid pCR.BEV.2 cloned downstream of tandem CMV-IE
promoter and SV40 late promoter sequences present in plasmid pCMV.SV40L.cass. To produce plasmid pCMV.O.SV40L.BEV, the BEV polymerase structural gene was sub-cloned in the sense orientation as a BglII-to-BamHI fragment into BamF-iI-digested pCMV.SV40L.cass DNA.
Plasmid pCMV.O.SV40L.VEB
Plasmid pCMV.O.SV40L.VEB (Figure 19) comprises an antisense BEV polymerase structural gene derived from plasmid pCR.BEV.2 cloned downstream of tandem CMV-IE
promoter and SV40 late promoter sequences present in plasmid pCMV.SV40L.cass. To produce plasmid pCMV.O.SV40L.VEB, the BEV polymerase structural gene was sub-cloned in the antisense orientation as a BglII-to-BamHI fragment into BamHI-digested pCMV.SV40L.cass DNA.

~~ 6 -3 (S) CA 02513336 1999-03-19 , , - 48a -5. Test Plasmids Plasmid pCMV.BEVx2 Plasmid pCMV.BEVx2 (Figure 20) comprises a direct repeat of a complete BEV polymerase open reading frame under the control of the CMV-IE promoter sequence. In eukaryotic cells at least, the open reading frame located nearer the CMV-IE promoter is translatable. To produce pCMV.BEVx2, the BEV polymerase structural gene from plasmid pCR.BEV.2 was sub-cloned in the sense orientation as a BglII-to-BamHI
fragment into BamHI-digested pCMV.BEV.2, immediately downstream of the WO 99/49029. PCT/AU99/0019~

BEV polymerise structural gene already present therein.
Plasmid pCMV.BEVx3 Plasmid.pCMV.BEVx3 (Figure 21) comprises a direct repeat of three complete BEV
polymerise open reading frames under the control of the CMV-1 E promoter. To produce pCMV.BEVx3, the BEV polymerise fragment from pCR.BEV.2 was cloned in the sense orientation as a Bgl(I/BamHl fragment into the BamHl site of pCMV.BEVx2, immediately downstream of the BEV polymerise sequences already present therein.
Plasmid pCMV.BEVx4 Plasmid pCMV.BEVx4 (Figure 22) comprises a direct repeat of four complete BEV
polymerise open reading frames under the control of the CMV-1 E promoter. To produce pCMV.BEVx4, the BEV polymerise fragment from pCR.BEV.2 was cloned in the sense orientation as a BgIII/BamHl fragment into the BamHi site of pCMV.BEVx3, immediately downstream of the BEV polymerise sequences already present therein.
Plasmid pCMV.BEV.SV40L.BEV
Plasmid pCMV.BEV.SV40L.BEV(Figure 23) comprises a multiple structural gene unit comprising two BEV polymerise structural genes placed operably and separately under control of the CMV-IE promoter and SV40 late promoter sequences. To produce plasmid pCMV.BEV.SV40L.BEV, the translatable BEV polymerise structural gene present in pCR.BEV.2 was sub-cloned in the sense orientation as a Bglll-to BamHl fragment behind the SV40 late promoter sequence present in BamHl-digested pCMV.BEV.SV40L-O.
Plasmid pCMV.BEV.SV40L.VEB
Plasmid pCMV.BEV.SV40L.VEB (Figure 24) comprises a multiple structural gene unit comprising two BEV polymerise structural genes placed operably and separately under control of the CMV-IE promoter and SV40 late promoter sequences. To produce plasmid pCMV.BEV.SV40L.VEB, the translatable BEV polymerase structural gene present in pCR.BEV.2 was sub-cloned in the antisense orientation as a Bglll-to-BamHl fragment behind the SV40 late promoter sequence present in BamHl-digested pCMV.BEV.SV40L-O. In this plasmid, the BEV polymerase structural gene is expressed in the sense orientation under control of the CMV-IE promoter to produce a translatable mRNA, whilst the BEV polymerase structural gene is also expressed under control of the SV40 promoter to produce an antisense mRNA species.
Plasmid pCMV.BEV.GFP.VEB
Plasmid pCMV.BEV.GFP.VEB (Figure 25) comprises a BEV structural gene inverted repeat or palindrome, interrupted by the insertion of a GFP open reading frame (stuffer fragment) between each BEV structural gene sequence in the inverted repeat. To produce ptasmid pCMV.BEV.GFP.VEB, the GFP stuffer fragment from pCR.BgI-GFP-Bam was first sub-cloned in the sense orientation as a Bglll-to-BamHl fragment into BamHl-digested pCMV.BEV.2 to produce an intermediate plasmid pCMV.BEV.GFP
wherein the BEV polymerase-encoding and GFP-encoding sequences are contained within the same 5'-Bglll-to-BamHl-3' fragment. The BEV polymerise structural gene from pCMV.BEV.2 was then cloned in the antisense orientation as a Bglll-to-BamHl fragment into BamHl-digested pCMV.BEV.GFP. The BEV polymerise structural gene nearer the CMV IE promoter sequence in plasmid pCMV.BEV.GFP.VEB is capable of being translated, at least in eukaryotic cells.
Plasrnid pCMV.EGFP.BEV2.PFG
Plasmid pCMV.EGFP.BEV2.PFG (Figure 26) comprise a GFP palindrome, interrupted by the insertion of a BEV polymerise sequence between each GFP structural gene in the inverted repeat. To produce this plasmid the GFP fragment from pCR.BgI-GFP-Bam was cloned as a BgIII/BamHl fragment into the BamHl site of pCMV.EGFP.BEV2 in the antisense orientation relative to the CMV promoter.

' CA 02513336 1999-03-19 Plasmid pCMV.BEV.SV40LR
Plasmid pCMV.BEV:SV40LR (Figure 27) comprises a structural gene comprising the entire BEV polymerase open reading frame placed operably and separately under control of opposing CMV-IE promoter and SV40 late promoter sequences, thereby potentially producing BEV polymerase transcripts at least from both strands of the full-length BEV polymerase structural gene. To produce plasmid pCMV.BEV.SV40LR, the translatable BEV polymerase structural gene present in pCR.BEV.2 was sub-cloned, as a Bglll-to-BamHl fragment, into the unique Bglll site of plasmid pCMV.SV40LR.cass, such that the BEV open reading frame is present in the sense orientation relative to the CMV-IE promoter sequence.
Those skilled in the art will recognise that it is possible to generate a plasmid wherein the BEV polymerase fragment from pCR.BEV.2 is inserted in the antisense orientation, relative to the CMV IE promoter sequence, using this cloning strategy. The present invention further encompasses such a genetic construct.

Genetic constructs comprising the porcine a-'t,3-gatactosyltransferase (Gait) structural gene sequence or sequences operably connected to the CMV promoter sequence andlor the SV40L promoter sequence 1. Commercial Plasmids Plasmid pcDNA3 Plasmid pcDNA3 is commercially available from Invitrogen and comprises the CMV
IE
promoter and BGHpA transcription terminator, with multiple cloning sites for the .
insertion of structural gene sequences there between: The plasmid further comprises the ColE1 and fl origins of replication and neomycin-resistance and ampicillin resistance genes.

~6-3 (S) CA 02513336 1999-03-19 2. Intermediate Plasmids Plasmid pcDNA3.Galt Plasmid pcDNA3.Galt (BresaGen Limited, South Australia, Australia; Figure 28) is plasmid pcDNA3 (Invitrogen) and comprises the cDNA sequence encoding porcine gene alpha-1,3-galactosyltransferase (Gait) operably under the control of the CMV-IE promoter sequence such that it is capable of being expressed therefrom. To produce plasmic~ pcDNA3.Galt, the porcine gene alpha-1,3-galactosyltransferase cDNA was cloned as an EcoRI fragment into the EcoRI cloning site of pcDNA3. The plasmid further comprises the ColEl and'fl origins of replication and the neomycin and ampicillin-resistance genes.
3. Control Plasmids Plasmid pCMV.Galt Plasmid pCMZI'.Galt (Figure 29) is capable of expressing the Galt structural gene under the control of the CMV-IE promoter sequence. To produce plasmid pCMV.Galt, the Galt sequence from plasmid pcDNA3.Galt was excised as an EcoRI fragment and cloned in the sense orientation into the EcoRI site of plasmid pCMV.cass (Figure 2).
Plasmid pCMV.EGFP.Galt Plasmid pCMV.EGFP.Galt (Figure 30) is capable of expressing the Galt structural gene as a Galt fusion polypeptide under the control of the CMV-IE promoter sequence. To produce plasmid pCMV.EGFP.Galt, the Galt sequence from pCMV.GaIt (Figure 29) was excised as a BgIII/BamHI fragment and cloned into the BamHI site of pCMV.EGFP.

~~6-3 (S) CA 02513336 1999-03-19 - 52a -Plasmid pCMV.Galt.GFP
Plasmid pCMV.GaIt.GFP (Figure 31) was produced by cloning the Galt cDNA as an EcoRI fragment from pCDNA3 into EcoRI-digested pCMV.EGFP in the sense orientation. This plasmid serves as both a control and construct intermediate.

WO 99/49029 PCT/AU99/0019~

Plasmid pCMV.GaIt.SV40L.0 The plasmid pCMV.GaIt.SV40L.0 (Figure 32) comprises a Galt structural gene cloned downstream of the CMV promoter present in pCMV.SV40L.cass. To produce the plasmid the Galt cDNA fragment from pCMV.GaIt was cloned as a Bglll/BamHl into Bglll-digested pCMV.SV40L.cass in the sense orientation.
Plasmid pCMV.O.SV40L.tIaG
The plasmid pCMV.O.SV40L.tIaG (Figure 33) comprises a Galt structural gene clone in an antisense orientation downstream of the SV40L promoter present in pCMV.SV40L.cass. To produce this plasmid the Galt cDNA fragment from pCMV.GaIt was cloned as a Bglll/BamHl into BamHl-digested pCMV.SV40L.cass in the antisense orientation.
Plasmid pCMV:O.SV40L.Galt , The plasmid pCMV.O.SV40L.Galt (Figure 34) comprises a Galt structural gene cloned downstream of the SV40L promoter present in pCMV.SV40L.cass. To produce the plasmid the Galt cDNA fragment from pCMV.GaIt was cloned as a BgIIIBamHI into BamHl-digested pC-MV.SV40L.cass~in the sense orientation.
4. Test Plasmids Plasmid pCMV.Galtx2 Plasmid pCMV.Galtx2 (Figure 35) comprises a direct repeat of a Galt open reading frame under the control of the CMV IE promoter sequence. In eukaryotes cells at least, the open reading frame located nearer the CMV-IE promoter is translatable. To produce pCMV.Galtx2, the Galt structural gene from pCMV.Gait was excised as a Bglil/BamHl fragment and cloned in the sense orientation into the BamHl cloning site of pCMV.GaIt.
Plasmid pCMV.Galtx4 Plasmid pCMV.Galtx4 (Figure 36) comprises a quadruple direct repeat of a Galt open reading frame under the control of the CMV IE promoter sequence. In eukaryotes cells at least, the open reading frame located nearer the CMV-IE promoter is translatable.
To produce pCMV.Galtx4, the Galtx2 sequence from pCMV.Galtx2 was excised as a BgRIIBamHI fragment and cloned in the sense orientation into the 8amHl cloning site of pCMV.Galtx2.
Plasmid pCMV.GaIt.SV40L.Galt The plasmid pCMV.GaIt.SV40L.Galt (Figure 37) is designed to express two sense transcripts of Gait, one driven by the CMV promoter, the other by the SV40L
promoter.
I0 To produce the plasmid a Galt cDNA fragment from pCMV.GaIt was cloned as a Bgili/BamHl fragment into Bglll-digested pCMV.O.SV40.Galt in the sense orientation.
Plasmid pCMV.GaItSV40L.tIaG
The piasmid pCMV.GaIt.SV40.tlaG (Figure 38) is designed to express a sense transcript of Galt driven by the CMV promoter and an antisense transcript driven by the SV40L promoter. To produce the plasmid a Galt cDNA fragment from pCMV.GaIt was cloned as a Bglll/BamHl fragment into Bglll-digested pCMV.O.SV40.taIG in the sense orientation.
Piasmid pCMV.GaItGFP.tIaG
Plasmid pCMV.Ga~.GFP.tIaG (Figure 39) comprise a Galt palindrome, interrupted by the insertion of a GFP sequence between each Galt structural gene in the inverted repeat. To produce this plasmid the Bglll/BamHi Galt cDNA fragment from pCMV.GaIt was cloned into the BamHl site of pCMV:GaIt.GFP in the antisense relative to the CMV
promoter.
Plasmid pCMV.EGFP.GaIt.PFG
The plasmid pCMV.EGFP.GaIt.PFG (Figure 40) comprises a GFP palindrome, interrupted by the insertion of a Galt sequence between each GFP structural gene of the inverted repeat, expression of which is driven by the CMV promoter. To produce ~,2~6-3 (S) this plasmid the Galt sequences from pCMV.Galt were cloned as a BglII/BamHI fragment into BamHI-digested pCMV.EGFP in the sense orientation to produce the intermediate pCMV.EGFP.Galt (not shown); following this further GFP
sequences from pCR.Bgl-pCMV.EGFP.Galt in the antisense orientation.
Plasmid pCMV.Galt.SV40LR
The plasmid pCMV.Galt.SV40LR (Figure 41) is designed to express Galt cDNA sequences cloned between the opposing CMV and SV40L promoters in the expression cassette pCMV.SV40LR.cass. To produce this plasmid Galt sequences from pCMV.Galt were cloned as a BglII/BamHI fragment in BglII-digested pCMV.SV40LR.cass in the sense orientation relative to the 35S promoter.

Genetic constructs comprising PVY Nia sequences operably linked to the 35S promoter sequence and/or the SCBV promoter sequence 1. binary vector Plasmi.d pART27 Plasmid pART27 is binary vector, specifically designed to be compatible with the pART7 expression cassette. It contains bacterial origins of replication for both E. coli and Agrobacterium tumefaciens, a spectinomycin resistance gene for bacterial selection, left and right T-DNA borders for transfer of DNA from Agrobacterium to plant cells and a kanamycin resistance cassette to permit selection of transformed plant cells. The kanamycin resistance cassette is located between the T-DNA borders, pART27 also contains a unique NotI restriction site which 2 s-3 (s) permits cloning of constructs prepared in vectors such as pART7 to be cloned between the T-DNA borders. Construction of pART27 is described in Gleave, AP (1992).
When cloning NotI inserts into this vector, two insert orientations can be. obtained. In all the following examples the same insert orientation, relative to the direction of the 35S promoter in the described pART7 constructs was chosen; this was done to minimise any experimental artefacts that may arise from comparing different constructs with different insert orientations.
2. Commercial plasmids Plasmid pBC(KS-) Plasmid pBC(KS-) is commercially available from Stratagene and comprises the LacZ promoter sequence and lacZ-alpha transcription terminator, with a multiple cloning site for the insertion of structural gene sequences therein.
The plasmid further comprises the ColEl and fl origins of replication and a chloroamphenicol-resistance gene.
Plasm~.d pSP72 Plasmid pSP72 is commercially available from Promega and contains a multiple cloning site for the insertion of structural gene sequences therein. The plasmid further comprises the ColEl origin of replication and an ampicillin-resistance gene.
3. Expression cassettes Plasmid pART7 Plasmid pART7 is an expression cassette designed to drive expression of sequences cloned behind the 35S
promoter. It contains a polylin3ter to assist cloning and a ~,',~6-3 (s) region of the octipine synthase terminator. The 35S
expression cassette is flanked by two NotI restriction sites which permits cloning into binary expression vectors, such as pART27 which contains a unique NotI site. Its construction is described in Gleave, AP (1992), a map is shown in Figure 42.
Plasmid pART7.35S.SCBV.cass Plasmid p35S.CMV.cass was designed to express two separate gene sequences cloned into a single plasmid. To create this plasmid, sequences corresponding to the NOS
terminator and the SCBV promoter were amplified by PCR then cloned in the polylinker of pART7 between the 35S promoter and OCS.
The resulting plasmid has the following arrangement of elements:
35S promoter - polylinker 1 - NOS terminator - SCBV promoter - polylinker 2 - OCS terminator.
Expression of sequences cloned into polylinker 1 is controlled by the 35S promoter, expression of sequences cloned into polylinker 2 is controlled by the SCBV promoter.
The NOS terminator sequences were amplified from the plasmid pAHC27 (Christensen and Quail, 1996) using the two oligonucleotides; ' NOS 5' (forward primer; SEQ TD 9) 5'-GGATTCCCGGGACGTCGCGAATTTCCCCCGATCGTTC-3': and NOS 3' (reverse primer; SEQ TD 10) 5'-CCATGGCCATATAGGCCCGATCTAGTAACATAG-3' ,2~6-3 (S) - 57a -Nucleotide residues 1 to 17 for NOS~5' and 1 to 15 for NOS 3' represent additional nucleotides designed to assist in construct preparation by adding additional restriction sites. For NOS 5' these are BamHI, SmaI, AatII
and the first 4 bases of an NruI site, for NOS 3' these are NcoI and SfiI sites. The remaining sequences for each oligonucleotide are homologous to the 5' and 3' ends respectively of NOS sequences in pAHC 27.
The SCBV promoter sequences were amplified from the plasmid pSCBV-20 (Tzafir et al., 1998 Plant Molecular Biology 38:347-56) using the two oligonucleotides (SEQ ID
NOS: 11 and 12):
SCBV 5':5'-CCATGGCCTATATGGCCATTCCCCACATTCAAG-3'; and SCBV 3':5'-AACGTTAACTTCTACCCAGTTCCAGAG-3' Nucleotide residues 1 to 17 of SCBV 5' encode Ncol and Sfil restriction sites designed to assist in construct preparation, the remaining sequences are homologous to upstream sequences of the SCMV promoter region. Nucleotide residues 1 to 9 of SCBV 3' encode Psp10461 and Hpal restriction sites designed to assist in construct preparation, the remaining sequences are homologous to the reverse and complement of sequences near the transcription initiation site of SCBV.
Sequences amplified from pScBV 20 using PCR and cloned into pCR2.1 (Invitrogen) to produce pCR.NOS and pCR.SCBV respectively. Smal IISfiI cut pCR.NOS and SfiIIHpaI cut pCR.SCBV were ligated into Sma I cut pART7 and a plasmid with a suitable orientation was chosen and designated pART7.35S.SCBV.cass, a map of this construct is shown in Figure 43.
4. Intermediate constructs Plasmid pBC.PVY
A region of the PVY genome was amplified by PCR using reverse-transcribed RNA
isolated from PVY-infected tobacco as a template using standard protocols and cloned info a plasmid pGEM 3 (Stratagene), to create pGEM.PVY. A Sall/Hindlll fragment from pGEM.PVY, corresponding to a Sall/Hindlll fragment positions 1536-2270 of the PVY strain O sequence (Acc. No D12539, Genbank), was then subcloned into the plasmid pBC (Stratagene Inc_) to create pBC.PVY (Figure 44).
Plasmid pSP72.PVY
Plasmid pSP72.PVY was prepared by inserting an EcoRl/Salt fragment from pBC.PVY
into EcoRI/Sall cut pSP72 (Promega). This construct contains additional restriction sites flanking the PVY insert which were used to assist subsequent manipulations. A
map of this construct is shown in Figure 45.
Plasmid CIapBC.PVY
Plasmid Cla pBC.PVY was prepared by inserting a CIaIISalI fragment from pS~P72.PVY

WO 99149029 PC'C/AU99/00195 into Clal/Sal I cutpBC (Stratagene). This construct contains additional restriction sites flanking the PVY insert which were used to assist subsequent manipulations. A
map of this construct is shown in Figure 46.
Plasmid pBC.PVYx2 Plasmid pBC.PVYx2 contains two direct head-to-tail repeats of the PVY
sequences derived from pBC.PVY. The plasmid was generated by cloning an AccI/Clal PVY
fragment from pSP72.PVY info Accl cut pBC.PVY and is shown in Figure 47.
Plasmid pSP72.PVYx2 Plasmid pSP72.PVYx2 contains two direct head-to-tail repeats of the PVY
sequences derived from pBC.PVY. The plasmid was generated by cloning an Accl/Clal PVY
fragment from pBc.PVY-into Accl cut pSP72.PW and is shown in Figure 48.
I S Plasmid pBC.PVYx3 Plasmid pBC.PVYx3 contains three direct head-to-tail repeats of the PVY
sequences derived from pBC.PVY. The plasmid was prepared by cloning an Accl/Clal PVY
fragriient from pSP72.PVY into Accl cut pBC.PVYx2 and is shown in Figure 49.
Plasmid pBC.PVYx4 Plasmid pBC.PVYx4 contains four direct head-to-tail repeats of the PVY
sequences derived from pBC.PVY. The plasmid was prepared by cloning the direct repeat of PVY
sequences from pSP72.PVYx2 as an Accl/Clal fragment into Accl cut pBC.PVYx2 and is shown in Figure 50:
Plasmid pBC.PVY.LNYV
All attempts to create direct palindromes of PVY sequences failed, presumably such sequence arrangements are unstable in commonly used E. coli cloning hosts.
Interrupted palindromes however proved stable.

~."~6-3 (S) To create interrupted palindromes of PVY sequences a "stuffer" fragment of approximately 360 by was inserted into Cla pBV.PVY downstream of the PVY sequences. The stuffer fragment was made as follows:
A clone obtained initially from a cDNA library prepared from lettuce necrotic yellows virus (LNYV) genomic RNA (Deitzgen et a1, 1989), known to contain the 4b gene of the virus, was amplified by PCR using the primers (SEQ ID
NOS: 13 and 14):
LNYV 1:5~-ATGGGATCCGTTATGCCAAGAAGAAGGA-3~; and LNYV 2:5'-TGTGGATCCCTAACGGACCCGATG-3~
The first 9 nucleotide of these primers encode a BamHI site, the remaining nucleotides are homologous to sequences of the LNYV 4b gene.
Following amplification, the fragment was cloned into the EcoRI site of pCR2.1 (Stratagene). This EcoRI
fragment was cloned into the EcoRI site of C1a pBC.PVY to create the intermediate plasmid pBC.PVY.LNYV which is shown in Figure 51.
Plasmi.d pBC.PVY.LNYV.PVY
The plasmid pBC.PVY.LNYV.PVY contains an interrupted direct repeat of PVY sequences. To create this plasmid a HpaI/HincII fragment from pSP72 was cloned into SmaI-digested pBC.PVY.LNYV and a plasmid containing the sense orientation isolated, a map of this construct is shown in Figure 52.

~26-3 (S) Plasmid pBC.PVY.LNYV.YVP~
The plasmid pBV.PVY.LNYV.YVP~ contains a partial interrupted palindrome of PVY sequences. One arm of the palindrome contains all the PVY sequences from pBC.PVY, the other arm contains part of the sequences from PVY, corresponding to sequences~between the EcoRV and HincII
sites of pSP72.PVY. To create this plasmid an EcoRV/HincII
fragment from pSP72.PVY was cloned into Smal-digested pBC.PVY.LNYV and a plasmid containing the desired orientation isolated, a map of this construct is shown in Figure 53.
Plasmid pBC.PVY.LNYV.YVP
The plasmid pBC.PVY.LNYV.YVP contains an interrupted palindrome of PVY sequences. To create this plasmid a HpaI/HincII fragment from pSP72 was cloned into Sma-digested pBC.PVY.LNYV and a plasmid containing the antisense orientation isolated, a map of this construct is shown in Figure 54.
5. Control plasmids Plasmids pART7.PVY & pART27.PVY
Plasmid pART7.PVY~ (Figure 55) was designed to express PVY sequences driven by the 35S promoter. This plasmid serves as a control construct in these experiments, against which all other constructs was compared. To generate this plasmid a ClaI/AccI fragment from Cla pBC.PVY
was cloned into ClaI-digested pART7 and a plasmid with expected to express a sense PVY sequence with respect to the PVY genome, was selected. Sequences consisting of the 35S
promoter, PvY sequences and the OCS terminator were excised as a NotI fragment and cloned into NotI-digested pART27, a ~~26-3 (S) ' ' - 62 -plasmid with the desired insert orientation was selected and designated pART27.PVY.
Plasmids pART7.35S.PVY.SCBV.O & pART27.35S.PVY.SCBV.O
Plasmid pART7.35S.PVY.SCBV.O (Figure 56) was designed to act as a control for co-expression of multiple constructs from a single plasmid in transgenic plants. The 35S promoter was designed to express PVY sense sequences, whilst the SCBV promoter was empty. To generate this plasmid, the PVY fragment from Cla pBC.PVY was cloned as a XhoI/EcoRI
fragment into XhoI/EcoRI-digested pART7.35S.SCBV:cass to create p35S.PVY.SCBV>O. Sequences consisting of the 35S
promoter driving sense PVY sequences and the NOS terminator and the SCBV promoter and OCS terminator were excised as a NotI fragment and cloned into pART27, a plasmid with the desired insert orientation was isolated and designated pART27.35S.PVY.SCBV.O.
Plasmids pART7.35S.O.SCBV.PVY & pART27.35S.O.SCBV.PVY
Plasmid pART7.35S.O.SCBV.PVY (Figure 57) was designed to act as an additional control for co-expression of multiple constructs from a single plasmid in transgenic plants. No expressible sequences were cloned behind the 35S
promoter, whilst the SCBV promoter drove expression of a PVY
sense fragment. To generate this plasmid, the PVY fragment from Cla pBC.PVY was cloned as a Clal fragment into ClaI-digested pART7.35S.SCBV.cass, a plasmid containing PVY
sequences in a sense orientation was isolated and designated p35S.O.SCBV.PVY. Sequences, consisting of the 35S promoter and NOS terminator, the SCBV promoter driving sense PVY
sequences and the OCS terminator were excised as a NotI
fragment and cloned into pART27, a plasmid with the desired ~~26-3 (S) - 62a -insert orientation was isolated and designated pART27.35S.O.SCBV.PVY.
Plasmids pART7.35S.O.SCBV.YVP & pART27.35S.O.SCBV.YVP
Plasmid pART7.35S.O.SCBV.YVP (Figure 58) was designed to act as an additional control for co-expression of multiple constructs from a single plasmid in transgenic plants. No expressible sequences were cloned behind the 35S
promoter, whilst the SCBV promoter drove expression of a PVY
antisense fragment. To generate this plasmid, the PVY
fragment from Cla pBC.PVY was cloned as a ClaI fragment into Clal-digested p35S.SCBV.cass, a plasmid containing PCY
sequences in an antisense orientation was isolated and designated p35S.O.SCBV.YVP. Sequences, consisting of the 35S promoter and NOS terminator, the SCBV promoter driving sense PVY sequences and the OCS terminator were excised as a NotI fragment and cloned into pART27, a plasmid with the desired insert orientation was isolated and designated pART27.35S.O.SCBV.YVP.
6. Test plasmids Plasmids pART7.PVYx2 & pART27.PVYx2 Plasmid pART7:PVYx2 (Figure 59) was designed to express a direct repeat of PVY
sequences driven by the 35S promoter in transgenic plants. To generate this plasmid, direct repeats from pBC.PVYx2 were cloned as a XhoIIBamHI fragment into XhoI/BamHl cut pART7_ Sequences consisting of the 35 S promoter, direct repeats of PVY and the OCS terminator were excised as a Notl fragment from pART7.PVYx2 and cloned into Notl-digested pART27, a plasmid with the desired insert orientation was selected and designated pART27.PVYx2.
Plasmids pART7.PVYx3 ~ pART27.PVYx3 Plasrnid pART7.PVYx3 (Figure 60) was designed to express a direct repeat of three PVY sequences driven by the 35S promoter in transgenic plants. To generate this plasmid, direct repeats from pBC.PVYx3 were cloned as a XhoI/BamHl fragment into Xhol/BamHl cut pART7. Sequences consisting of the 35S promoter, direct repeats of PVY and OCS terminator were excised as a Notl fragment from pART.PVYx3 and cloned info Notl-digested pART27, a plasmid with the desired insert orientation was selected and designated pART27.PVYx3.
Plasmids pART7.PVYx4 & pART27.PVYx4 .
Plasmid pART7.PVYx4 (Figure 61) was designed to express a direct repeat of four PVY sequences driven by the 35S promoter in transgenic plants. To generate this plasmid, direct repeats from pBC.PVYx4 were cloned as a XhoI/BamHl fragment into xhoIIBamHI cut pART7. Sequences consisting of the 35S promoter, direct repeats of PVY and the OCS terminator were excised as a Notl fragment from pART7.PVYx3 and cloned into Notl-digested pART27, a piasmid with the desired insert orientation was selected and designated pART27.PVYx3.
Plasmids pART7.PVY.LNYV.PVY & pART27.PVY.LNYV.PVY
Plasmid pART7.P1/Y.LNYV.PW (Figure 62) was designed to express the interrupted direct repeat of PVY sequences driven by the 35S promoter in transgenic plants. This construct was prepared by cloning the interrupted direct repeat of PVY from ' CA 02513336 1999-03-19 pBC.PVY.LNYV.PVY as a Xhol/Xbal fragment into pART7 digested with Xhol/Xbal.
Sequences consisting of the 35S promoter, the interrupted direct repeat .of PVY
sequences and the OCS terminator were excised from pART7.PVY.LNYV.PVY as a Not) fragment and cloned into Notl-digested pART27, a plasmid with the desired insert orientation was selected and designated pART27.PVY.LNYV.PVY.
Plasmids pART7.PVY.LNYV.YVPe & pART27.PVY.LNYV.YVPe Plasmid pART7.PVY.LNYV.YVPe (Figure 63) was designed to express the partial interrupted palindrome of PVY sequences driven by the 35S promoter in transgenic plants. This construct was prepared by cloning the partial interrupted palindrome of PVY sequences from pBC.PVY.LNYV.YVPe as a Xhol/Xbal fragment into pART7 digested with Xhol/Xbal. Sequences consisting of the 35S promoter, the partial interrupted palindrome of PVY sequences and the OCS terminator were excised from pART7.PVY.LNYV.YVPe as a Notl fragment and cloned into Notl-digested pART27, a plasmid with the desired insert orientation was selected and designated pART27.PVY.LNYV.YVP.
Plasmids pART7.PVY.LNYV.YVP ~ pART27.PVY.LNYV.YVP
Plasmid pART7.PVY.LNYV.YVP (Figure 64) was designed to express the interrupted palindrome of PVY sequences driven by the 35S promoter in transgenic plants.
This construct was prepared by cloning the interrupted palindrome of PVY sequences from pBC.PVY.LNYV.YVPe as a Xhol/Xbai fragment into pART7 digested with Xhol/Xbal.
Sequences consisting of the 35S promoter, the interrupted palindrome of PVY
sequences and the OCS terminator were excised from pART7.PVY.LNYV.YVP as a Notl fragment and cloned into pART27, a plasmid with the desired insert orientation was selected and designated pART27.PVY.LNYV.YVP.
Plasmids pART7.35S.PVY.SCBV.YVP & pART27.35S.PVY.SCBV.YVP
Plasmid pART7.35S.PVY.SCBV.YVP (Figure 65) was designed to co-express sense and antisense constructs in transgenic plants. To generate this plasmid the PVY

fragment from Cla pBC.PVY was cloned as a XhoI/EcoRl fragment into xhol/EcoRl-digested p35S.SCBV.O.SCBV.YVP. Sequences, consisting of the 35S promoter driving sense PVY sequences and the NOS terminator and the SCBV promoter driving antisense PVY and the OCS terminator were excised as a Notl fragment and cloned into pART27, a plasmid with the desired insert orientation was isolated and designated pART27.35S.PVY.SCBV.YVP.
Plasmids pART7.35S.PVYx3.SCBV.YVPx3 & pART27.35S.PVYx3.SCBV.YVPx3 Plasmid pART7.35S.PVYx3.SCBV.YVPx3 (Figure 66) was designed to co-express sense and antisense repeats of PVY in transgenic plants. to generate this plasmid, the intermediate pART7.35S.O.SCBV.YVPx3 was constructed by cloning the triple direct PVY repeat from CIapBC.PVYx3 as a CIaI/Accl fragment into Cla-digested p35S.SCBV.cass and isolating a plasmid with an antisense orientation. for p35S.PVYx3.SCBV.YVPx3 the triple direct PVY repeat from Cla pBC.PVYx3 was cloned as a Kpnl/Smal fragment into Kpnl/Smal-digested p35S.O.SCBV.YVPx3 to create p35S.PVYx3.SCBV.YVPx3. Sequences including both promoters, terminators and direct PVY repeats were isolated as a Notl fragment and cloned into pART27. A
plasmid with an appropriate orientation was chosen and designated pART27.35S.PVYx3.SCBV.
Plasmids pART7.PVYx3.LNYV.YVPx3 & pART27.PVYx3.LNYV.YVPx3 Plasmid pART7.PVYx3.t_NYV.YVPx3 (Figure 67) was designed to express triple repeats of PVY sequences as an interrupted palindrome. To generate this plasmid an intermediate, pART7x3.PVY.LNYV.YV was constructed by cloning a PVY.LNYV.YVP
fragment from pBC.PVY.LNYV.YVP as an AccIIClaI fragment into the plasmid pART7.PVYx2. pART7.35S.PVYx3.LNYV.YVPx3, was made by cloning an additional PVY direct repeat from pBC.PVYx2 as an Accl/Clal fragment into Clal digested pART7x3.PVY.LNYV.YVP. Sequences from pART7.35S.PVYx3.LNYV.YVPx3, including the 35S promoter, all PVY sequences and the OCS terminator were excised as a Notl fragment and cloned into Notl-digested pART27, a plasmid with an appropriate orientation was chosen and designated pART27.35S.PWx3.LNYV.
Ptas~nids pARTT.PVY mufti & pART27.PVY mufti Piasmid pART7.35S.PW mufti (Figure 68) was designed to express higher order direct repeats of regions of PVY sequences in transgenic plants. Higher order direct repeats of a 72,bp of the PVY Nia region from PW were prepared by annealing two partially complementary oligonucleotides as follows (SEQ ID NOS :15 and 16 ) PW1:
5'-TAATGAGGATGATGTCCCTACCTTTAATTGGCAGAAATTTCTGTGGAAAGACAG
GGAAATCTTTCGGCATTT-3'; and PVY2:
5'= tTCTGCCAATTAAAG GTAG G GACATCATC CTCATTAAAATG C C GAAAGATT
IS TCCCTGTCTTTCCACAGAAAT-3' The oligonucleotides were phosphorylated with T4 polynucleotide kinase, heated and cooled slowly to permit self annealing, ligated with T4 DNA ligase, end-filled with Klenow polyrnerase and cloned info pCR2_1 (Invitrogen). Plasmids containing multiple repeats were isolated and sequences were cloned as EcoRl fragments in a sense orientation into EcoRl-digested pART7, to create the intermediate pART7.PVY
mufti.
to create pART27.PW mufti; the 35S promoter, PVY sequences and. the ACS
terminator were excised as a Notl fragment and cloned into Notl-digested pART27.
A plasmid with an appropriate insert orientation was isolated and designated , pART27.PVY mufti.

Inactivation of virus gene expression in mammals oral immune lines are created by expressing viral sequences in stably transformed cell lines.
In particular, lytic viruses are used for this approach since cell lysis provides very simple screens and also offer the ability to directly select for potentially rare transformation events which might create viral immunity. Sub-genomic fragments derived from a simple single stranded RNA virus (Bovine enterovirus - BEV) or a complex double stranded DNA virus, Herpes Simplex Virus I (HSV I) are cloned into a suitable vector and expressed in transformed cells. Mammalian cell lines are transformed with genetic constructs designed to express viral sequences driven by the strong cytomegalovirus (CMV-IE) promoter. Sequences utilised include specific viral replicase genes. Random "shotgun" Libraries comprising representative viral gene sequences, may also be used and the introduced dispersed nucleic acid molecule, to target the expression of virus sequences.
Exemplary genetic constructs for use in this procedure; comprising nucleotide sequences derived from the BEV RNA-dependent RNA polymerase gene, are presented herein.
For viral polymerase constructs, large numbers (approximately 100) of transformed cell lines are generated and infected with the respective virus. For cells transformed with shotgun libraries very large numbers (hundreds) of transformed lines are generated and screened in bulk for viral immunity. Following virus challenge, resistant cell lines are selected and analysed further to determine the sequences conferring immunity thereon.
Resistant cell lines are supportive of the ability of the introduced nucleotide sequences to inactivate viral gene expression in a mammalian system.

Additionally, resistant lines obtained from such experiments are used to more precisely define molecular and biochemical characteristics of the modulation which is observed.

Induction of virus resistance in transgenic plants Agrobacterium tumefaciens, strain LBA4404, was transformed independently with the constructs pART27.PVY, pART27.PVYx2, pART27.PVYx3, pART27.PVYx4, pART27.PVY.LNYV.PVY, pART27.PVY.LNYV.YVPe, pART27.PVY.LNYV.YVP, pART27.35S.PVY.SCBV.O, pART27.35S.O.SCBV.PVY, pART27.35S.O.SCBV.YVP, pART27.35S.PVY.SCBV.YVP, pART27.35S.PVYx3.SCBV.YPVx3, pART27.PVYx3.LNYV.YVPx3 and pART27.PVYx10, using tri-parental matings. DNA
mini-preps from these strains were prepared and examined by restriction with Notl to ensure they contained the appropriate binary vectors.
Nicotiana tabaccum (cultivar W38) were transformed with these Agrobacterium strains using standard procedures. Putative transformed shoots were excised and rooted on media containing kanamycin. Under these conditions we have consistently observed that only transgenic shoots will root on kanamycin plates. Rooted shoots were transferred to soil and allowed to establish. After two to three weeks, vigorous plants with at least three sets of leaves were chosen and infected with PVY.
Viral inoculum was prepared from W38 tobacco previously infected with the virus, approximately 2 g of leaf material, showing obvious viral symptoms were ground with carbarundum in 10 ml of 100mM Na phosphate buffer (pH 7.5). the inoculum was diluted to 200 ml with additional Na phosphate buffer. Two leaves from each transgenic plant were sprinkled with carbarundum, then 0.4 ml of inoculum was applied to each leaf and leaves rubbed fairly vigorously with fingers. Using this procedure 100% of non-transgenic control plants were infected with PVY.

~26-3 (S) CA 02513336 1999-03-19 ' - 69 -To assay for viral resistance and immunity transgenic plants are monitored for symptom development.
The PVY strain (PVY-D, an Australian PVY isolate) gives obvious symptoms on W38 tobacco, a vein clearing symptom is readily observed on the two leaves above the inoculated leaves, subsequent leaves show uniform chlorotic lesions.
Symptom development was monitored over a six week period.
Transgenic lines were described as resistant if they showed reduced viral symptoms, which manifests as a reduction in the leaf are showing chlorotic lesions.
Resistance ranges from very strong resistance where only a few viral lesions are observed on a plant to weak resistance which manifests as reduced symptoms on leaves that develop late in plant growth.
Transgenic plants which showed absolutely no evidence of viral symptoms were classified as immune. To ensure these plants were immune they were re-inoculated with virus, most plants remained immune, the few that showed symptoms were reclassified as resistant.
For plant lines generated Southern blots are performed, resistance in subsequent generations is monitored to determine that resistance/immunity is transmissible.
Additionally, the breadth of viral resistance is monitored by challenging lines with other PVY strains, to determine .
whether host range susceptibility is modified.
Results from these experiments are described in Table 1. These data indicate that constructs comprising tandem repeats of target gene sequence, either in the configuration of palindromes, interrupted palindromes as direct repeat sequences, are capable of conferring viral resistance and/or immunity in transgenic plants.

~~6-3 (S) CA 02513336 1999-03-19 Accordingly, such inverted and/or direct repeat sequences modulate expression of the virus target gene in the transgenic plant.
Constructs combining the use of direct and inverted repeat sequences, namely pART27.35S.PVYx3.SCBV.YVPx3 and pART27.PVYx3.LNYV.YVPx3, are also useful in modulating gene expression.

Inactivation of Galt in animal cells To assay for Galt inactivation, porcine PK2 cells were transformed with the relevant constructs. PK2 cells constitutively express Galt enzyme, the activity of which results in the addition of a variety of a-1,3-galactosyl groups to a range of proteins expressed on the cell surface of these cells. Cells were transformed using lipofectin and stably transformed lines were selected using genetecin.
As an initial assay cell lines were probed for the presence of the Galt-encoded epitope, i.e. a-1,3-galactosyl moieties decorating cell surface proteins, using the lectin IB4. IB4 binding was assayed either in situ or by FRCS
sorting.
For in situ binding, cells were fixed to solid supports with cold methanol for 5 mins, cells were rinsed in PBS (phosphate buffered saline) and non-specific IB4 binding was blocked with 1~ BSA in PHS for 10 mins. Fixed cells were probed using 20 ug/ml IB4-biotin (Sigma) in 1°s BSA, PBS
for 30 mins at room temperature, cells were washed in PBS
then probed with a 1:200 dilution of ExtrAvidin*-FITC
(Sigma) in PBS for 30 minx followed by further rinses in *Trade-mark ~~26-3 (S) CA 02513336 1999-03-19 . . . - 70a -PBS. Cells were then examined using fluorescence microscopy, under these conditions the outer surface of PK2 control cells uniformly stained green.
For FACS analysis, cells were suspended after treatment with trypsin, washed in HBSS/Hepes (Hank's buffered saline solution with 20 mM Hepes, pH7.4) and probed with 10 ug/ml IB4-biotin (Sigma) in HBSS/Hepes for 45 rains at 4'C. Cells were washed in HBSS/Hepes, probed with a 1:200 dilution of ExtrAvidin*-FITC (Sigma) in HBSS/Hepes for 45 rains at 4'C at and rinsed in cold HBSS/Hepes prior to FACS
*Trade-mark PCT/AU99 Ot9~

sorting.
Using this approach transformed cell fines are assayed for Galt inactivation and quantitative assessment of construct effectiveness is determined. Moreover cell fines S showing Gait inactivation are isolated and subject to further molecular analyses to determine the mechanism of gene inactivation.

6-3 (S~ CA 02513336 1999-03-19 . ~ - 72 -Table 1 Z

Q

(~ tn Z N

O
z a N ~r r o~ r r ~r co . ca ~t o E'n-.o J Z Z

a a ~

0 ~ ~ .

w u. -_ ~

~ ~ ~- ef tn I' O O O 00 N r tJJ ~ ~
U J
. ~ m ~ E:..
a a i.u v ~fi N ~ 00 00 ~ M ~ <D f~ .
-O
Z a ("~,~ Q) M r e- O N OD f' , ~ (i5.O 00 r' r N N N N . r N N r r a V - Q ~ d ,~. a ., ~ U a ~ ~ ~ ~ a: a.
~ X X X V m ~ > a. .
O ~ ~- m V ~..~ ~
V 0. O cUn...~ -~ J J
O (L
.

_ . ., .
.

M M M

'' Q N N N N N N N: N N N N
J .
a Q d a a a Q Q .Q a a a a a a a a a a a a a a ~., o . .
WO 99/49029 PC'T/AU99/00195 REFERENCES
1. An et al. (1985) EMBO J 4:277-284.
2. Armstrong, et aLPlant Cell Reports 9: 335-339, 1990.
3. Ausubel, F.M. et a1.(1987) In: Current Protocols in Molecular Biology, Wley (nterscience (ISBN 047140338)..
4. Chalfie,M: et al (1994) Science 263: 802-805.
5. Christensen, A.H. and Quail, P.H_ (1996) Transgenic Research 5: 213-218.
6. Christou, P., et al. Plant Physiol 87: 671-674, 1988.
7. Cormack, B. et al (1996) Gene 173: ~33-38.
8. ' Crossway et aL, Mol. Gen. Genet. 202:179-185, 1986.
9. borer, D.R., and Henikoff, S. (1994) Cell7: 993-1002.
10. Fromm et al. Proc. NatG Acad. Sci. (USA) 82:5824-5828, 1985.
11. Gleave, A.P. (1992) Plant Molecular Biology 20:1203-1207.
12. Hanahan, D. (1983) J. Mol_Biol. 166: 557-560.
1S 13. Herrera-Estelta et al., Nature 303: 209-213, 1983a.
14. Herrera-Estella et aL,EMBO J. 2: 987-995, 1983b.
15. Herrera-Estetla ef al. In: Plant Genetic Engineering, Cambridge University Press, N.Y., pp 63-93, 1985.
16. Inouye, S, and Tsuji, F:I. (1994) FEBS Lefts. 341: 277-280.
17. Jackson, i.J. (1995) Ann. Rev. Genet. 28: 189-217.
18. Krens, F.A., et al., Nature 296: 72-74, 1982.
19. Kwon, B.S. et al. (1988) Biochem. Biophys. Res. Comm. 153:1301-1309.
20. - Pal-Bhadra, M. ef al. (1997) Cell 90: 479-490.
21. Paszkowski et al., EM80 J. 3:2717-2722, 1984 2S 22. Prasher, D.C. et al. (1992) Gene 111: 229-233.
23. Sanford, J.C., et al., Particulate Science and Technology 5: 27-37, 1987.

CA 02513336 1999-03-.19 SEQUENCE LISTING
<110> Benitec Australia Limited AND
State of Queensland through its Department of Primary Industries .
<120> Control of gene expression <130> 30165-1 <140> 2,323,726 <141> 1999-03-19 <150> AU PP2492 <151> 1998-03-20 <150> AU PP2499 <151> 1998-03-20 <160> 16 <170> PatentIn version 3.0 <210> 1 <211> 26 <212> DNA
<213> jellyfish <400> 1 agatctgtaa acggccacaa gttcag 26 <210> 2 <211> 26 <212> DNA
<213> jellyfish <400> 2 ggatccttgt acagctcgtc catgcc 26 <210> 3 <211> 74 <212> DNA
<213> virus <400> 3 gtcgacaata aaatatcttt attttcatta catctgtgtg ttggtttttt gtgtgatttt 60 tgcaaaagcc tagg 74 <210> 4 <211> 31 <212> DNA
<213 > virus <400> 4 gtcgacgttt agagcagaag taacacttcc g 31 <210> 5 <211> 38 <212 > DNA
<213 > virus <400 > 5 cggcagatct aacaatggca ggacaaatcg agtacatc 38 <210 > 6 <211> 31 ' <212 > DNA
<213 > virus <400> 6 cccgggatcc tcgaaagaat cgtaccactt c 3I
<210 > 7 <211> 29 <212 > DNA
<213> virus <400> 7 gggcggatcc ttagaaagaa tcgtaccac 29 <210> 8 <211> 28 <212> DNA
<213> virus <400> 8 cggcagatct ggacaaatcg agtacatc 28 <210> 9 <211> 37 <212> DNA
<213> agrobacterium <400> 9 ggattcccgg gacgtcgcga atttcccccg atcgttc 37 <210> 10 <211> 33 <212> DNA
<213> agrobacterium <400> 10 ccatggccat ataggcccga tctagtaaca tag 33 <210> 11 _ <211> 33 <212> DNA
<213> virus <400> 11 ccatggccta tatggccatt ccccacattc aag 33 <210> 12 <211> 27 <212> DNA
<213> virus <400> 12 aacgttaact tctacccagt tccagag 27 <210> 13 <211> 28 <212> DNA
<213> virus <400> 13 atgggatccg ttatgccaag aagaagga 26 <210> 14 <211> 24 <212> DNA
<213> virus <400> 14 tgtggatccc taacggaccc gatg 24 <210> 15 <211> 72 <212> DNA
<213> virus <400> 15 taatgaggat gatgtcccta cctttaattg gcagaaattt ctgtggaaag acagggaaat 60 ctttcggcat tt 72 <210> 16 <211> 72 <212> DNA
<213> virus <400> 16 ttctgccaat taaaggtagg gacatcatcc tcattaaaat gccgaaagat ttccctgtct 60 ttccacagaa at 72

Claims (24)

1. An isolated nucleic acid molecule comprising two or more copies of a ribonucleotide (RNA) sequence which are about 20-100 nucleotides in length and wherein a first copy is at least 80% identical to the nucleotide sequence of a target gene or a region thereof, and at least a second copy is 80% identical to a nucleotide sequence complementary to the target gene or the region thereof, wherein said nucleic acid molecule is capable of reducing expression of the target gene in a mammalian cell when the nucleic acid molecule is introduced into said mammalian cell.
2. The nucleic acid molecule of claim 1, wherein the ribonucleotide (RNA) sequence is capable of encoding an amino acid sequence of the target gene.
3. The nucleic acid molecule of claim 1, wherein the two or more copies of the ribonucleotide (RNA) sequence are an inverted repeat in the same nucleic acid strand.
4. The nucleic acid molecule of claim 3, wherein the two or more copies of the ribonucleotide (RNA) sequence are separated by a stuffer fragment or intergenic region to facilitate secondary structure formation.
5. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule prevents or reduces translation of mRNA of the target gene.
6. The nucleic acid molecule of claim 1 or 5, wherein said animal cell is a vertebrate cell.
7. The nucleic acid molecule of claim 1 or 5, wherein said mammalian cell is a human cell.
8. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is at least 90% identical to the nucleotide sequence of the target gene or the region thereof, and at least a second copy is 90% identical to a nucleotide sequence complementary to the target gene or the region thereof.
9. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is at least 95% identical to the nucleotide sequence of the target gene or the region thereof, and at least a second copy is 95% identical to a nucleotide sequence complementary to the target gene or the region thereof.
10. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is identical to the nucleotide sequence of the target gene or the region thereof, and at least a second copy is identical to a nucleotide sequence complementary to the target gene or the region thereof.
11. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said nucleic acid molecule consists essentially of ribonucleotides.
12. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein at least one of said first and second copy is comprised at least partially of ribonucleotide analogues.
13. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is 24 nucleotides in length.
14. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is 23 nucleotides in length.
15. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is 22 nucleotides in length.
16. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is 21 nucleotides in length.
17. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is 19 nucleotides in length.
18. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein said first copy is 18 nucleotides in length.
19. The nucleic acid molecule of any one of claims 13-18, wherein said first copy is about the same length as said second copy.
20. The nucleic acid molecule of any one of claims 13-18, wherein said first copy is the same length as said second copy.
21. The nucleic acid molecule of claim 1, 5, 6, or 7, wherein the first and second copies are in separate nucleic acid strands.
22. An in vitro or ex-vivo method of delaying, repressing, or otherwise reducing the expression of a target gene in a mammalian cell, comprising introducing the nucleic acid molecule according to any one of claims 1-5 and 8-21 to the mammalian cell.
23. The method of claim 22, wherein the mammalian cell is an isolated human cell.
24. Use of the nucleic acid molecule according to any one of claims 1-5 and 8-21 for delaying, repressing, or otherwise reducing the expression of a target gene in a mammalian cell.
CA002513336A 1998-03-20 1999-03-19 Control of gene expression in a non-human eukaryotic cell, tissue or organ Abandoned CA2513336A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPP2499A AUPP249998A0 (en) 1998-03-20 1998-03-20 Gene expression I
AUPP2492A AUPP249298A0 (en) 1998-03-20 1998-03-20 Synthetic genes and genetic constructs comprising same I
USPP2499 1998-03-20
USPP2492 1998-03-20
CA002487328A CA2487328A1 (en) 1998-03-20 1999-03-19 Sirna for control of gene expression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002487328A Division CA2487328A1 (en) 1998-03-20 1999-03-19 Sirna for control of gene expression

Publications (1)

Publication Number Publication Date
CA2513336A1 true CA2513336A1 (en) 1999-09-30

Family

ID=25645735

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002323726A Expired - Lifetime CA2323726C (en) 1998-03-20 1999-03-19 Control of gene expression
CA002513336A Abandoned CA2513336A1 (en) 1998-03-20 1999-03-19 Control of gene expression in a non-human eukaryotic cell, tissue or organ
CA002487328A Abandoned CA2487328A1 (en) 1998-03-20 1999-03-19 Sirna for control of gene expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002323726A Expired - Lifetime CA2323726C (en) 1998-03-20 1999-03-19 Control of gene expression

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002487328A Abandoned CA2487328A1 (en) 1998-03-20 1999-03-19 Sirna for control of gene expression

Country Status (21)

Country Link
US (6) US20030074684A1 (en)
EP (5) EP1857549B1 (en)
JP (4) JP4187413B2 (en)
KR (3) KR101085210B1 (en)
CN (3) CN101818145A (en)
AT (2) ATE526405T1 (en)
AU (6) AU743316C (en)
BR (1) BRPI9908967B1 (en)
CA (3) CA2323726C (en)
CZ (1) CZ295108B6 (en)
DK (1) DK1624060T3 (en)
ES (2) ES2374290T3 (en)
GB (1) GB2353282C (en)
HK (1) HK1035742A1 (en)
HU (1) HU230353B1 (en)
NZ (2) NZ547283A (en)
PL (1) PL343064A1 (en)
SG (2) SG115493A1 (en)
SK (1) SK287538B6 (en)
WO (1) WO1999049029A1 (en)
ZA (1) ZA200004507B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102719454A (en) * 2012-06-15 2012-10-10 华南农业大学 Optimized sulfide quinine oxidation-reduction enzyme gene and expression vector thereof

Families Citing this family (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1068311B2 (en) * 1998-04-08 2020-12-09 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
US8598332B1 (en) * 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
AR020078A1 (en) * 1998-05-26 2002-04-10 Syngenta Participations Ag METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL
US6939712B1 (en) * 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
DE19956568A1 (en) * 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
WO2000063364A2 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
BR0010496A (en) * 1999-05-10 2002-04-02 Syngenta Participations Ag Regulation of viral gene expression
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
DE60037735T2 (en) 1999-08-26 2009-01-02 Calgene Llc, Davis PLANTS WITH CHANGED MULTIPLE-SATURATED FATTY ACIDS
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
CN1426466A (en) * 2000-03-17 2003-06-25 贝尼泰克澳大利亚有限公司 Genetic silencing
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
AU2001297906B2 (en) 2000-10-31 2007-07-19 Commonwealth Scientific And Industrial Research Organisation Method and means for producing barley yellow dwarf virus resistant cereal plants
ES2728168T3 (en) 2000-12-01 2019-10-22 Max Planck Gesellschaft Small RNA molecules that mediate RNA interference
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
NZ526507A (en) 2001-01-26 2005-07-29 Commw Scient Ind Res Org Methods and means for producing efficient silencing construct using recombinational cloning
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2003070972A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
US7691995B2 (en) 2001-07-12 2010-04-06 University Of Massachusetts In vivo production of small interfering RNAS that mediate gene silencing
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
EP1409506B1 (en) 2001-07-23 2012-05-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US7612194B2 (en) 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
US20050037989A1 (en) * 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Rna interference mediated inhibition of map kinase genes
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US7893248B2 (en) 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
EP1474433A4 (en) * 2002-02-20 2005-02-23 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7662952B2 (en) 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
GB2397062B (en) 2002-02-20 2005-06-15 Sirna Therapeutics Inc RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA)
AU2003212089B2 (en) * 2002-03-14 2008-08-21 Commonwealth Scientific And Industrial Research Organisation Methods and means for monitoring and modulating gene silencing
EP2294915A3 (en) 2002-03-21 2011-04-13 Monsanto Technology LLC Nucleic acid constructs and methods for producing altered seed oil compositions
US7166771B2 (en) 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
US7566813B2 (en) 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
PT1504126E (en) 2002-05-03 2014-06-02 Univ Duke A method of regulating gene expression
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
WO2004015107A2 (en) 2002-08-05 2004-02-19 Atugen Ag Further novel forms of interfering rna molecules
WO2004015062A2 (en) 2002-08-12 2004-02-19 New England Biolabs, Inc. Methods and compositions relating to gene silencing
AU2003295322B2 (en) 2002-08-21 2009-06-18 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20040152651A1 (en) * 2002-11-01 2004-08-05 Rana Tariq M. Regulation of transcription elongation factors
US7078234B2 (en) 2002-12-18 2006-07-18 Monsanto Technology Llc Maize embryo-specific promoter compositions and methods for use thereof
AU2004225483B2 (en) 2003-03-28 2009-07-23 Monsanto Technology, Llc Novel plant promoters for use in early seed development
AU2005212433B2 (en) 2003-05-23 2010-12-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
JP2006526394A (en) * 2003-06-03 2006-11-24 ベニテック オーストラリア リミテッド Double-stranded nucleic acid
WO2004108903A2 (en) 2003-06-06 2004-12-16 Arborgen, Llc Plant transformation and selection
EP1636385A4 (en) * 2003-06-24 2010-06-02 Mirus Bio Corp Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
BRPI0412282A (en) * 2003-07-02 2006-09-19 Musc Found For Res Dev specific and nonspecifically induced dsrna immunity in crustaceans and other invertebrates, and bioliberation vehicles for use in these
WO2005009134A1 (en) * 2003-07-21 2005-02-03 Lifecell Corporation ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE
CA2536112A1 (en) 2003-08-20 2005-03-03 Northern Sydney And Central Coast Area Health Service Methods for enhancing embryo viability
IL157538A0 (en) 2003-08-21 2004-03-28 Bar Ilan Res & Dev Company Ltd Plant resistant to cytoplasm-feeding parasites
US20080044906A1 (en) * 2003-09-12 2008-02-21 Peter Michael Waterhouse Modified Gene-Silencing Nucleic Acid Molecules and Uses Thereof
CA2548080A1 (en) 2003-11-05 2005-05-26 University Of Pittsburgh Porcine isogloboside 3 synthase protein, cdna, genomic organization, and regulatory region
JP2007512027A (en) 2003-11-21 2007-05-17 レビビコア, インコーポレイテッド Use of interfering RNA in the production of transgenic animals
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
AU2004304665B2 (en) 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
AR047598A1 (en) 2004-02-10 2006-01-25 Monsanto Technology Llc TRANSGENIZED CORN SEED WITH GREATER AMINO ACID CONTENT
US7683237B2 (en) 2004-02-10 2010-03-23 Monsanto Technology Llc Maize seed with synergistically enhanced lysine content
US7855323B2 (en) 2004-02-10 2010-12-21 Monsanto Technology Llc Recombinant DNA for gene suppression
US20060075515A1 (en) 2004-08-11 2006-04-06 Luethy Michael H Enhanced zein reduction in transgenic corn seed
DK1725660T3 (en) 2004-03-05 2011-08-29 Benitec Inc Expression cassettes with multiple promoters for simultaneous delivery of RNAi agents
EP2433492B1 (en) 2004-03-17 2018-04-25 Revivicor Inc. Tissue products derived from animals lacking any expression of functional alpha 1,3 galactosyltransferase
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005095614A1 (en) 2004-03-31 2005-10-13 Commonwealth Scientific And Industrial Research Organistion Genes involved in plant fibre development
PL1818405T3 (en) 2004-04-09 2015-11-30 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
ES2715640T3 (en) 2004-04-22 2019-06-05 Commw Scient Ind Res Org Synthesis of long chain polyunsaturated fatty acids by recombinant cells
AU2005238034A1 (en) 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Of New York Inhibition of hairless protein mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
MX2007004310A (en) 2004-10-13 2007-06-18 Univ Georgia Res Found Nematode resistant transgenic plants.
CA2582550C (en) 2004-10-25 2019-06-25 Devgen Nv Rna constructs
US7368086B2 (en) * 2004-10-29 2008-05-06 Invitrogen Corporation Functionalized fluorescent nanocrystals, and methods for their preparation and use
US8404927B2 (en) * 2004-12-21 2013-03-26 Monsanto Technology Llc Double-stranded RNA stabilized in planta
WO2006071219A1 (en) 2004-12-28 2006-07-06 Pioneer Hi-Bred International, Inc. Improved grain quality through altered expression of seed proteins
WO2006076423A2 (en) 2005-01-12 2006-07-20 Monsanto Technology, Llc Genes and uses for plant improvement
EP2338905B1 (en) 2005-02-23 2017-11-29 North Carolina State University Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes
DE202005004135U1 (en) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Multi-component packaging with applicator
CA2605068A1 (en) * 2005-04-15 2006-10-26 The Board Of Regents Of The University Of Texas System Delivery of sirna by neutral lipid compositions
WO2006113743A2 (en) * 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
CA2606220A1 (en) 2005-04-19 2006-12-21 Basf Plant Science Gmbh Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants
WO2006127310A2 (en) 2005-05-25 2006-11-30 Pioneer Hi-Bred International, Inc. Methods for improving crop plant architecture and yield
US8853489B2 (en) 2005-09-16 2014-10-07 Devgen Nv Transgenic plant-based methods for plant pests using RNAi
HUE031692T2 (en) 2005-09-16 2017-07-28 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
CN101268194A (en) 2005-09-20 2008-09-17 巴斯福植物科学有限公司 Methods for controlling gene expression using ta-siRNA
EP1934348B1 (en) 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
EP1947925B1 (en) 2005-10-20 2013-12-25 Commonwealth Scientific And Industrial Research Organisation Cereals with altered dormancy
WO2007084922A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
AR059257A1 (en) 2006-02-09 2008-03-19 Pioneer Hi Bred Int GENES TO IMPROVE THE EFFICIENCY OF THE USE OF NITROGEN IN CROPS
AR059433A1 (en) 2006-02-10 2008-04-09 Monsanto Technology Llc IDENTIFICATION AND USE OF WHITE GENES FOR THE CONTROL OF PARASITE PLANT NEMATODES
CN101421406B (en) 2006-02-13 2016-08-31 孟山都技术有限公司 For producing nucleic acid construct and the method that the seed oil of change forms
CN105385679B (en) 2006-02-13 2020-05-26 孟山都技术有限公司 Selecting and stabilizing dsRNA constructs
FR2898908A1 (en) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Process, useful to prepare differentiated avian cells from avian stem cells grown in culture medium, comprises induction of stem cells differentiation by inhibiting expression/activity of gene expressed in the stem cells e.g. Nanog gene
US7557266B2 (en) 2006-04-19 2009-07-07 Pioneer Hi-Bred International, Inc. Isolated polynucleotide molecules corresponding to mutant and wild-type alleles of the maize D9 gene and methods of use
WO2008006169A1 (en) 2006-07-12 2008-01-17 Commonwealth Scientific And Industrial Research Organisation Polynucleotides and methods for enhancing salinity tolerance in plants
EP2059596B1 (en) * 2006-08-31 2017-10-04 Monsanto Technology, LLC Phased small rnas
CN101195821A (en) 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 Method for improving insect resistance of plant by using RNAi technique
WO2008086325A1 (en) 2007-01-10 2008-07-17 Sanofi-Aventis Method for determining the stability of organic methyleneamines in the presence of semicarbazide-sensitive amine oxidase
ATE533353T1 (en) 2007-02-05 2011-12-15 Univ Singapore PUTATIVE CYTOKININ RECEPTOR AND METHOD FOR USE THEREOF
US8067390B2 (en) * 2007-03-02 2011-11-29 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using siRNA in neutral liposomes
US8796442B2 (en) 2007-03-21 2014-08-05 Brookhaven Science Associates, Llc. Combined hairpin-antisense compositions and methods for modulating expression
US9662383B2 (en) 2007-03-26 2017-05-30 University Of Massachusetts Compositions and methods for increasing immunogenicity of glycoprotein vaccines
EP2164863A4 (en) 2007-06-15 2010-07-28 Univ Arkansas Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
US8642846B2 (en) 2007-08-13 2014-02-04 Commonwealth Scientific And Industrial Research Organisation Barley with low levels of hordeins
US20110131668A1 (en) 2007-08-14 2011-06-02 Commonwealth Scientific And Industrial Research Organisation Improved gene silencing methods
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
CA2706439C (en) 2007-11-20 2015-04-21 Pioneer Hi-Bred International, Inc. Maize ethylene signaling genes and modulation of same for improved stress tolerance in plants
CA2706805A1 (en) 2007-11-27 2009-06-04 Commonwealth Scientific And Industrial Research Organisation Plants with modified starch metabolism
US8809626B2 (en) 2007-12-21 2014-08-19 Keygene N.V. Trichome specific promoters
CN102056605A (en) * 2008-04-04 2011-05-11 罗伯特·绍尔 Pharmaceutical composition
EP2279265B1 (en) 2008-04-24 2014-08-27 NewSouth Innovations Pty Limited Cyanobacteria saxitoxin gene cluster and detection of cyanotoxic organisms
WO2009132351A2 (en) * 2008-04-25 2009-10-29 University Of Medicine And Dentistry Of New Jersey Anti-sense microrna expression vectors
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2294184A4 (en) 2008-06-30 2013-03-06 Mesoblast Inc Treatment of eye diseases and excessive neovascularization using a combined therapy
AU2009273754B2 (en) 2008-07-21 2016-07-14 Commonwealth Scientific And Industrial Research Organisation Improved cottonseed oil and uses
BRPI0920827A2 (en) 2008-09-29 2015-08-18 Monsanto Technology Llc Mon87705 soybean transgenic event and methods for its detection
MX2011003616A (en) 2008-10-30 2011-08-15 Pioneer Hi Bred Int Manipulation of glutamine synthetases (gs) to improve nitrogen use efficiency and grain yield in higher plants.
CN102272157B (en) 2008-11-07 2015-11-25 研究发展基金会 For suppressing composition and the method for the formation of CRIPTO/GRP78 mixture and signal
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
US20110287088A1 (en) 2008-12-03 2011-11-24 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
WO2010065867A1 (en) 2008-12-04 2010-06-10 Pioneer Hi-Bred International, Inc. Methods and compositions for enhanced yield by targeted expression of knotted1
US8497075B2 (en) 2008-12-09 2013-07-30 Novartis Ag Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
EP3293257B1 (en) 2009-03-20 2021-08-11 Mesoblast, Inc. Production of reprogrammed pluripotent cells
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
US8987553B2 (en) 2009-04-14 2015-03-24 Pioneer Hi Bred International Inc Modulation of ACC synthase improves plant yield under low nitrogen conditions
WO2010118477A1 (en) 2009-04-17 2010-10-21 Molecular Plant Breeding Nominees Ltd Plant promoter operable in endosperm and uses thereof
BRPI1013833A2 (en) 2009-04-20 2019-04-09 Monsanto Technology Llc resistance to multiple viruses in plants
US9320755B2 (en) 2009-06-05 2016-04-26 Centenary Institute Of Cancer Medicine And Cell Biology Therapeutic and diagnostic molecules
WO2010142465A1 (en) 2009-06-08 2010-12-16 Nunhems B.V. Drought tolerant plants
MX2012001080A (en) 2009-07-24 2012-03-26 Pionner Hi Bred International Inc The use of dimerization domain component stacks to modulate plant architecture.
CN101760555B (en) * 2009-09-30 2012-06-27 西南大学 Method for identifying single-copy transgenic tobacco based on PCR technology
US20110252505A1 (en) 2009-10-02 2011-10-13 Pioneer Hi-Bred International, Inc. Down-Regulation of ACC Synthase for Improved Plant Performance
WO2011073326A2 (en) 2009-12-18 2011-06-23 Novartis Ag Organic compositions to treat hsf1-related diseases
WO2011085062A1 (en) 2010-01-06 2011-07-14 Pioneer Hi-Bred International, Inc. Identification of diurnal rhythms in photosynthetic and non-photosynthetic tissues from zea mays and use in improving crop plants
EP2534489A1 (en) 2010-02-10 2012-12-19 Novartis AG Methods and compounds for muscle growth
CN107090453A (en) * 2010-05-10 2017-08-25 德克萨斯A&M大学系统 The composition of expressing gene product, organism, system and method in plant
CN107974457A (en) 2010-05-28 2018-05-01 纽海姆有限公司 The plant of fruit size increase
ES2817780T3 (en) 2010-07-12 2021-04-08 The State Of Israel Ministry Of Agriculture And Rural Development Agricultural Res Organization A R Isolated polynucleotides and methods and plants that use them to regulate the acidity of plants
EP3192880B1 (en) 2010-08-18 2019-10-09 Fred Hutchinson Cancer Research Center Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
US9233997B2 (en) * 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
US20120107355A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
HUE044426T2 (en) 2010-10-28 2019-10-28 Benitec Biopharma Ltd Hbv treatment
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
AU2011325875B2 (en) 2010-11-04 2016-03-17 Arista Cereal Technologies Pty Ltd High amylose wheat
NZ609567A (en) 2010-11-05 2015-05-29 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
ES2680636T3 (en) 2011-02-14 2018-09-10 Revivicor Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
US10030245B2 (en) 2011-03-23 2018-07-24 E I Du Pont De Nemours And Company Methods for producing a complex transgenic trait locus
EP2794643A1 (en) 2011-04-29 2014-10-29 Pioneer Hi-Bred International Inc. Down-regulation of a homeodomain-leucine zipper i-class homeobox gene for improved plant performance
US20140216118A1 (en) 2011-06-14 2014-08-07 Synthon Biopharmaceuticals B.V. Compositions and Methods for Making and Biocontaining Auxotrophic Transgenic Plants
EP2723874A2 (en) 2011-06-21 2014-04-30 Pioneer Hi-Bred International, Inc. Methods and compositions for producing male sterile plants
WO2013066805A1 (en) 2011-10-31 2013-05-10 Pioneer Hi-Bred International, Inc. Improving plant drought tolerance, nitrogen use efficiency and yield
US9357722B2 (en) 2011-11-04 2016-06-07 Arista Cereal Technologies Pty Limited High amylose wheat-II
UA116097C2 (en) 2011-12-11 2018-02-12 Зе Стейт Оф Ізраел, Міністрі Оф Агрікалче Енд Руерал Девелопмент, Агрікалчерал Рісьоч Організейшн, (А.Р.О.), Волкані Сентре Methods of modulating stomata conductance and plant expression constructs for executing same
AU2012327162A1 (en) 2011-12-27 2013-07-11 Commonwealth Scientific And Industrial Research Organisation Production of dihydrosterculic acid and derivatives thereof
AU2012324024B2 (en) 2011-12-27 2016-06-16 Nuseed Global Innovation Ltd Processes for producing lipids
CA2860432A1 (en) 2011-12-27 2013-07-04 Commonwealth Scientific And Industrial Research Organisation Simultaneous gene silencing and supressing gene silencing in the same cell
AU2013208720A1 (en) 2012-01-09 2014-07-24 Arrowhead Research Corporation RNAi agents to treat Beta-Catenin related diseases
AU2013209279B2 (en) 2012-01-11 2017-12-14 North Carolina State University Method for modulating plant root architecture
WO2013138309A1 (en) 2012-03-13 2013-09-19 Pioneer Hi-Bred International, Inc. Genetic reduction of male fertility in plants
US9783814B2 (en) 2012-03-13 2017-10-10 Pioneer Hi-Bred International, Inc. Genetic reduction of male fertility in plants
CN104619164B (en) 2012-04-25 2018-11-16 联邦科学技术研究组织 high oleic acid oil
WO2014027021A1 (en) 2012-08-16 2014-02-20 Vib Vzw Means and methods for altering the lignin pathway in plants
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
CN104955947A (en) 2013-01-29 2015-09-30 格拉斯哥大学董事会 Methods and means for increasing stress tolerance and biomass in plants
CN105143470B (en) 2013-02-28 2020-06-09 德克萨斯大学系统董事会 Methods for classifying cancer as susceptible to TMEPAI-directed therapy and treating the cancer
US20160002648A1 (en) 2013-03-11 2016-01-07 Mei Guo Genes for improving nutrient uptake and abiotic stress tolerance in plants
WO2014164074A1 (en) 2013-03-13 2014-10-09 Pioneer Hi-Bred International, Inc. Enhanced nitrate uptake and nitrate translocation by over-expressing maize functional low-affinity nitrate transporters in transgenic maize
US20160017360A1 (en) 2013-03-13 2016-01-21 Pioneer Hi-Bred International, Inc. Functional expression of bacterial major facilitator superfamily mfs gene in maize to improve agronomic traits and grain yield
BR112015023304A2 (en) 2013-03-14 2017-07-18 Pioneer Hi Bred Int method to improve abiotic stress tolerance of a plant, plant and seed
BR112015023700A2 (en) 2013-03-15 2017-07-18 Pioneer Hi Bred Int abiotic stress tolerance enhancement method in an agricultural crop plant, transgenic corn plant, plant cell, seed, method of down regulation of an endogenous acc oxidase gene in a corn plant.
EP2976429B1 (en) 2013-03-21 2017-04-19 VIB vzw Means and methods for the reduction of photorespiration in crops
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
AU2014278519B2 (en) 2013-06-11 2020-09-10 Syngenta Participations Ag Methods for generating transgenic plants
BR112015031257A2 (en) 2013-06-13 2017-08-29 Commw Scient Ind Res Org BARLEY WITH VERY LOW LEVELS OF HORDEINS
EP3682873A1 (en) 2013-06-25 2020-07-22 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for use in the treatment of persistent hiv infection
BR112016008172B1 (en) 2013-10-16 2021-06-15 The Australian National University METHOD FOR MODULATION OF PLANT GROWTH
ES2846758T3 (en) 2013-11-04 2021-07-29 Lifecell Corp Methods to remove alpha-galactose
EP3069137A1 (en) 2013-11-05 2016-09-21 Novartis Ag Organic compounds
US9803008B2 (en) 2013-11-28 2017-10-31 Csl Limited Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)
CA2933590C (en) 2013-12-11 2023-10-03 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
KR102466794B1 (en) 2013-12-18 2022-11-11 씨에스엘 리미티드 Method of treating wounds
US20170166920A1 (en) 2014-01-30 2017-06-15 Two Blades Foundation Plants with enhanced resistance to phytophthora
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
EP2966157B1 (en) 2014-07-07 2023-11-01 Nuseed Global Innovation Ltd Processes for producing industrial products from plant lipids
WO2016005449A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
US9517270B2 (en) 2014-12-08 2016-12-13 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CA2987111C (en) 2015-05-29 2024-01-02 Arcadia Biosciences Reduced gluten grains and compositions thereof
US10000766B2 (en) * 2015-07-17 2018-06-19 National Chung Hsing University Recombinant construct, recombinant microorganism, recombinant plant cell and method of providing plant with resistance against DNA virus and RNA virus
JP6978152B2 (en) 2015-09-04 2021-12-08 キージーン ナムローゼ フェンノートシャップ Multiphase spore reproductive gene
EP3349802B1 (en) 2015-09-14 2021-08-04 The Board of Regents of the University of Texas System Lipocationic dendrimers and uses thereof
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
JP2018535680A (en) 2015-11-18 2018-12-06 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション Rice grain with thick paste
EP3375445A4 (en) 2015-11-30 2019-08-07 Xie, Yanhui Use of akt2 in diagnosis and treatment of tumor
CA3016487A1 (en) 2016-03-18 2017-09-21 Marc C. Albertsen Methods and compositions for producing clonal, non-reduced, non-recombined gametes
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
AU2017267634C1 (en) 2016-05-16 2022-05-26 The Board Of Regents Of The University Of Texas System Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
WO2018035451A1 (en) 2016-08-19 2018-02-22 Calimmune, Inc. Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
EP3500279A4 (en) * 2016-08-19 2020-04-22 Calimmune, Inc. Methods and compositions for treating canine conditions using recombinant self-complementary adeno-associated virus
CN107841510B (en) * 2016-09-20 2021-02-09 中国科学院青岛生物能源与过程研究所 Method for controlling expression ratio of different genes horizontally after transcription of prokaryotic cell
JP2021519587A (en) 2018-03-30 2021-08-12 ユニバーシティ オブ ジュネーブ MicroRNA expression constructs and their use
CN112888440A (en) 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Use of Akt inhibitors in ophthalmology
US20220091137A1 (en) 2019-01-17 2022-03-24 Hoffmann-La Roche Inc. E3 ubiquitin ligase (ube3a) protein targets
EP3920889A4 (en) 2019-02-08 2022-12-07 Board of Regents, The University of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
EP4004212A1 (en) 2019-07-30 2022-06-01 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control
AU2021260578A1 (en) 2020-04-20 2022-11-03 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
IL298558A (en) 2020-05-27 2023-01-01 Antion Biosciences Sa Adapter molecules to re-direct car t cells to an antigen of interest
US20230266325A1 (en) 2020-06-30 2023-08-24 Lunglife Ai, Inc. Methods for detecting lung cancer
WO2022162015A1 (en) 2021-01-26 2022-08-04 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof
WO2023012342A1 (en) 2021-08-06 2023-02-09 Kws Vegetables B.V. Durable downy mildew resistance in spinach
WO2023020980A1 (en) 2021-08-16 2023-02-23 F. Hoffmann-La Roche Ag E3 ubiquitin ligase (ube3a) protein targets
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
WO2023230531A1 (en) 2022-05-24 2023-11-30 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US27783A (en) * 1860-04-10 Improvement in apparatus for evaporating sugar-juices
US114784A (en) * 1871-05-16 Improvement in compounds for cure of chills and fever
US86356A (en) * 1869-02-02 Improvement in the construction of fire-proof safes
US266005A (en) * 1882-10-17 William allen
US165894A (en) * 1875-07-20 Improvement in vessels for removing foul water from docks
US74684A (en) * 1868-02-18 of wallingford
US36197A (en) * 1862-08-12 Improvement in compound bullets for small-arms
US56235A (en) * 1866-07-10 Improvement in paring-knives
US3931397A (en) 1971-11-05 1976-01-06 Beecham Group Limited Biologically active material
US4024222A (en) 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4034323A (en) * 1975-03-24 1977-07-05 Oki Electric Industry Company, Ltd. Magnetic relay
US4283393A (en) 1979-03-13 1981-08-11 Merck & Co., Inc. Topical application of interferon inducers
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4605394A (en) 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
DE3208247A1 (en) 1982-03-08 1983-09-22 Philips Patentverwaltung Gmbh, 2000 Hamburg CUVETTE FOR THE ATOMIC ABSORPTION SPECTROMETRY
JPS5936698A (en) 1982-08-20 1984-02-28 Science & Tech Agency Recombinant dna recombined with gene of virus of hepatitis b, transformed animal cell, and preparation of protein of virus of hepatitis b
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
ATE198350T1 (en) 1983-10-20 2001-01-15 Univ New York State Res Found REGULATION OF GENE EXPRESSION THROUGH TRANSLATION INHIBITION USING A M-RNS DISABLED COMPLEMENTARY RNA
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5173410A (en) 1984-02-15 1992-12-22 Lubrizol Genetics Inc. Transfer vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4766072A (en) 1985-07-17 1988-08-23 Promega Corporation Vectors for in vitro production of RNA copies of either strand of a cloned DNA sequence
GB8521646D0 (en) 1985-08-30 1985-10-02 English Clays Lovering Pochin Inorganic fillers
CA1326450C (en) 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
US6617496B1 (en) 1985-10-16 2003-09-09 Monsanto Company Effecting virus resistance in plants through the use of negative strand RNAs
GB8601680D0 (en) 1986-01-23 1986-02-26 Agricultural Genetics Co Modification of plant viruses
IL81737A (en) 1986-03-28 1992-11-15 Calgene Inc Regulation of gene expression in plant cells
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5017488A (en) * 1986-04-01 1991-05-21 University Of Medicine And Dentistry Of New Jersey Highly efficient dual T7/T3 promoter vector PJKF16 and dual SP6/T3 promoter vector PJFK15
EP0278667B1 (en) * 1987-02-09 1994-07-20 Mycogen Plant Science, Inc. Hybrid RNA virus
PH24467A (en) 1987-03-03 1990-07-18 Hem Res Inc Synergistics interplay of lymphokines and dsrnas
US4950652A (en) 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
AU1820588A (en) 1987-07-17 1989-01-19 Hem Research, Inc. Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function
IE66830B1 (en) 1987-08-12 1996-02-07 Hem Res Inc Topically active compositions of double-stranded RNAs
IE72103B1 (en) 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
EP0306347B1 (en) 1987-09-04 1995-05-10 Hem Pharmaceuticals Corp. Diagnosis of double-stranded RNA deficiency states
US5874555A (en) 1987-10-30 1999-02-23 California Institute Of Technology Triple helices and processes for making same
US4963532A (en) 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
JP3046318B2 (en) 1987-12-15 2000-05-29 ジーン・シアーズ・ピーティーワイ・リミテッド Ribozyme
US5254678A (en) * 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
PH25365A (en) 1987-12-23 1991-05-13 Hem Research Rhase l inhibitor as a marker for virus infections
US5922602A (en) 1988-02-26 1999-07-13 Biosource Technologies, Inc. Cytoplasmic inhibition of gene expression
GB8810120D0 (en) 1988-04-28 1988-06-02 Plant Genetic Systems Nv Transgenic nuclear male sterile plants
CA1320446C (en) 1988-06-20 1993-07-20 William A. Carter Modulation of lymphokine-resistant cellular states by dsrnas
ATE103493T1 (en) 1988-07-07 1994-04-15 Hem Pharma Corp DIAGNOSIS AND TREATMENT OF CHRONIC FATIGUE.
US5597718A (en) * 1988-10-04 1997-01-28 Agracetus Genetically engineering cotton plants for altered fiber
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5434070A (en) * 1989-02-24 1995-07-18 The University Of Medicine And Dentistry Of New Jersey Reverse transcriptases from Escherichia coli and Myxococcus xanthus
US5780269A (en) 1989-02-24 1998-07-14 The University Of Medicine And Denistry Of New Jersey Hybrid molecules
US5405775A (en) * 1989-02-24 1995-04-11 The University Of Medicine And Dentistry Of New Jersey Retrons coding for hybrid DNA/RNA molecules
US5436141A (en) 1989-02-24 1995-07-25 University Of Medicine And Dentistry Of New Jersey Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products
DK0387775T3 (en) 1989-03-16 1996-11-04 Boehringer Ingelheim Int Genetic unit for inhibiting the function of RNA
US5034323A (en) 1989-03-30 1991-07-23 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
AU5630590A (en) 1989-04-05 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A clone of double-stranded rna virus applied to antibody production, study of retrovirus-like frameshifting and production of proteins in yeast
WO1990012094A1 (en) 1989-04-05 1990-10-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A clone of double-stranded rna virus and applications thereof
EP0473576A4 (en) 1989-05-19 1993-03-10 Hem Research, Inc. Short therapeutic dsrna of defined structure
US5122466A (en) 1989-06-13 1992-06-16 North Carolina State University Ballistic transformation of conifers
GB8916213D0 (en) 1989-07-14 1989-08-31 Ici Plc Dna constructs,cells and plants derived therefrom
HU214927B (en) 1989-08-10 1998-07-28 Plant Genetic Systems N.V. Process for producing plants with modified flower
US5747308A (en) 1989-10-25 1998-05-05 Celltech Therapeutics Limited Recombinant DNA method
US5939600A (en) * 1989-11-03 1999-08-17 Goldbach; Robert Willem Nucleic acids encoding tospovirus genome and expression thereof
HUT57265A (en) * 1989-11-03 1991-11-28 Zaadunie Bv Process for producing plants of diminished infection-sensitivity
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5578718A (en) * 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US6245560B1 (en) * 1990-01-18 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Vector with multiple target response elements affecting gene expression
JP2746480B2 (en) * 1990-01-18 1998-05-06 アメリカ合衆国 Vectors with multiple target response factors affecting gene expression
US5168064A (en) 1990-04-20 1992-12-01 The Regents Of The University Of California Endo-1,4-β-glucanase gene and its use in plants
GB9009307D0 (en) 1990-04-25 1990-06-20 Ici Plc Dna,constructs,cells and plant derived therefrom
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
AU8059891A (en) 1990-06-13 1992-01-07 Trustees Of Princeton University, The A (lac) repressor-hsv vp16 chimeric transcriptional activator protein system functioning in transfected mammalian cells
WO1992003454A1 (en) 1990-08-14 1992-03-05 Isis Pharmaceuticals, Inc. Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides
DE4027616A1 (en) * 1990-08-31 1992-03-05 Boehringer Mannheim Gmbh METHOD FOR DETERMINING POLYMERASE ACTIVITY
MX9100993A (en) 1990-09-10 1992-05-04 Us Agriculture RECOMBINANT SEQUENCE OF DNA ISOLATED AND ENZYME 1-AMINO CYCLOPROPAN-1-CARBOXYL SYNTHESE, RECOMBINANT
US5306862A (en) * 1990-10-12 1994-04-26 Amoco Corporation Method and composition for increasing sterol accumulation in higher plants
SE467358B (en) 1990-12-21 1992-07-06 Amylogene Hb GENETIC CHANGE OF POTATISE BEFORE EDUCATION OF AMYLOPECT TYPE STARCH
SE467160B (en) 1990-12-21 1992-06-01 Amylogene Hb GENETIC MODIFICATION OF POTATOIS BEFORE EDUCATION OF AMYLOST TYPE
JPH06505161A (en) 1991-01-25 1994-06-16 ユナイテッド・ステイツ・バイオケミカル・コーポレイション Regulation of nucleic acid translation
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
GB9106713D0 (en) 1991-03-28 1991-05-15 Ici Plc Dna,dna constructs,cells and plants derived therefrom
US6005167A (en) 1991-04-16 1999-12-21 Mogen International N.V. Male-sterile plants, method for obtaining male-sterile plants and recombinant DNA for use therein
US5683985A (en) 1991-04-18 1997-11-04 The Salk Institute For Biological Studies Oligonucleotide decoys and methods relating thereto
FR2675803B1 (en) 1991-04-25 1996-09-06 Genset Sa CLOSED, ANTISENSE AND SENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS.
GB9109063D0 (en) 1991-04-26 1991-06-12 Ici Plc Modification of lignin synthesis in plants
WO1992021757A1 (en) 1991-05-30 1992-12-10 Plant Genetic Systems, N.V. Nematode-responsive plant promoters
CA2112373C (en) 1991-07-11 2010-04-20 Timothy A. Holton Genetic sequences encoding flavonoid pathway enzymes and uses therefor
US6010908A (en) 1992-08-21 2000-01-04 The Regents Of The University Of California Gene therapy by small fragment homologous replacement
US5714323A (en) 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
CA2073630C (en) 1991-08-30 2007-12-11 Atsushi Ohshima Method for synthesizing single-stranded stem-loop dnas, the products and uses therefor
AU2928492A (en) 1991-11-20 1993-06-15 Mogen International N.V. A method for obtaining plants with reduced susceptibility to plant-parasitic nematodes
FR2685346B1 (en) * 1991-12-18 1994-02-11 Cis Bio International PROCESS FOR THE PREPARATION OF DOUBLE-STRANDED RNA, AND ITS APPLICATIONS.
ES2166361T3 (en) 1992-02-19 2002-04-16 State Of Oregon Acting By & Th PRODUCTION OF VIRUS RESISTANT PLANTS THROUGH THE INTRODUCTION OF INTRADUCIBLE VIRAL RNA OF POSITIVE SENSE.
DE4208107A1 (en) 1992-03-13 1993-09-16 Bayer Ag PSEUDORABIES VIRUS (PRV) POLYNUCLEOTIDES AND THEIR USE IN THE MANUFACTURE OF VIRUS RESISTANT EUKARYOTIC CELLS
US5593874A (en) * 1992-03-19 1997-01-14 Monsanto Company Enhanced expression in plants
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
GB9210273D0 (en) 1992-05-13 1992-07-01 Ici Plc Dna
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US6451603B1 (en) 1992-06-29 2002-09-17 Gene Shears Pty. Limited Ribozyme nucleic acids and methods of use thereof for controlling viral pathogens
ATE171210T1 (en) 1992-07-02 1998-10-15 Hybridon Inc SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTICS
JPH07503376A (en) 1992-07-30 1995-04-13 ケイヘーネ・エヌ・ベー DNA constructs and cells and plants derived therefrom
CA2106260A1 (en) * 1992-09-17 1994-03-18 Robert M. Kotin Human adeno-associated virus integration site dna and uses thereof
WO1994007367A1 (en) 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
AU674029B2 (en) 1992-10-15 1996-12-05 Syngenta Mogen Bv Genetic moderation or restoration of plant phenotypes
US6872872B1 (en) 1992-11-17 2005-03-29 E. I. Du Pont De Nemours And Company Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants
US6372965B1 (en) 1992-11-17 2002-04-16 E.I. Du Pont De Nemours And Company Genes for microsomal delta-12 fatty acid desaturases and hydroxylases from plants
ZA939767B (en) 1993-01-21 1994-09-14 Univ North Carolina State Nematode-resistant transgenic plants
CA2150133A1 (en) 1993-02-05 1994-08-18 Vincent Jean-Marie Armel Arondel Altered linolenic and linoleic acid content in plants
US6069298A (en) 1993-02-05 2000-05-30 Regents Of The University Of Minnesota Methods and an acetyl CoA carboxylase gene for conferring herbicide tolerance and an alteration in oil content of plants
EP0620281A3 (en) * 1993-03-31 1995-05-03 Mitsubishi Corp Oilseed crops producing valuable seeds having altered amino acid composition and fatty acid composition.
WO1994029465A1 (en) 1993-06-08 1994-12-22 Nunhems Zaden B.V. Process for generating male sterile plants
KR960704034A (en) 1993-07-19 1996-08-31 다니엘 엘. 캐시앙 Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and / or Multiplication of Infectious Disease Pathogens
US5739309A (en) 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
US5808036A (en) 1993-09-01 1998-09-15 Research Corporation Technologies Inc. Stem-loop oligonucleotides containing parallel and antiparallel binding domains
US5514546A (en) 1993-09-01 1996-05-07 Research Corporation Technologies, Inc. Stem-loop oligonucleotides containing parallel and antiparallel binding domains
ATE400651T1 (en) 1993-09-10 2008-07-15 Univ Columbia USE OF GREEN FLUORESCENT PROTEIN
GB9318927D0 (en) 1993-09-13 1993-10-27 Zeneca Ltd Regulation of senescence
CA2172153C (en) 1993-09-20 2010-03-09 John C. Reed Regulation of bcl-2 gene expression
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
GB9320548D0 (en) 1993-10-06 1993-11-24 Sandoz Ltd Improvements in or relating to organic compounds
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
FR2714383B1 (en) 1993-12-29 1996-02-09 Centre Nat Rech Scient Control of gene expression.
JP3691849B2 (en) 1994-01-05 2005-09-07 ジーン・シアーズ・ピーティーワイ・リミテッド Ribozymes targeting retroviral packaging sequences, expression constructs thereof, and recombinant retroviruses containing such constructs
US5849991A (en) * 1994-01-27 1998-12-15 Bresatch Limited Mice homozygous for an inactivated α 1,3-galactosyl transferase gene
AU706417B2 (en) 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5686649A (en) 1994-03-22 1997-11-11 The Rockefeller University Suppression of plant gene expression using processing-defective RNA constructs
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
US6054299A (en) * 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
EP0772678A4 (en) 1994-09-12 1999-10-20 Hope City Modulation of drug radiation resistant genes
US5576716A (en) * 1994-12-07 1996-11-19 Sadler; Kermit M. Owner oriented system for locating lost or stolen property
AU5741396A (en) 1995-05-11 1996-11-29 Hybridon, Inc. Pyrimidine targeting hairpin triplex-forming oligonucleotide s
US5691140A (en) 1995-05-18 1997-11-25 New England Biolabs, Inc. Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions
US5693773A (en) 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
EP0837624A1 (en) 1995-06-30 1998-04-29 DNA Plant Technology Corporation Delayed ripening tomato plants
FR2737501B1 (en) * 1995-07-31 1997-10-24 Transgene Sa NOVEL AUXILIARY VIRUSES FOR THE PREPARATION OF RECOMBINANT VIRAL VECTORS
AU6904596A (en) 1995-09-13 1997-04-01 Chiron Corporation Method and construct for screening for inhibitors of transcriptional activation
EP0851919A1 (en) 1995-09-20 1998-07-08 University of Massachusetts Worcester Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
PL187026B1 (en) 1995-10-06 2004-04-30 Plant Genetic Systems Nv Seeds dropping
JPH09110894A (en) 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk Hybric dna/rna oligonucleotide and antiviral agent
EP0771878A1 (en) 1995-10-31 1997-05-07 Plant Genetic Systems N.V. Plants with reduced glucosinolate content
US5773692A (en) 1995-12-12 1998-06-30 Her Majesty The Queen In Right Of Canada, As Represented By Agriculture And Agri-Food Canada Anti-sense RNA for CAB transcript to reduce chlorophyll content in plants
CA2190304A1 (en) 1995-12-15 1997-06-16 Elazar Rabbani Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
IT1283876B1 (en) 1996-01-12 1998-05-07 Univ Roma CHIMERIC RIBOZYME-SNRNA MOLECULES WITH CATALYTIC ACTIVITY FOR NUCLEAR-LOCATED RNA
EP0880598A4 (en) * 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
US5891855A (en) * 1996-02-12 1999-04-06 The Scripps Research Institute Inhibitors of leaderless protein export
JP3847366B2 (en) 1996-02-22 2006-11-22 アンジェスMg株式会社 Stationary mitotic cell growth agent using antisense oligonucleotide
US5989864A (en) * 1996-10-29 1999-11-23 Smithkline Beecham Corporation DNA encoding spo-rel polypeptides
WO1997034003A1 (en) 1996-03-13 1997-09-18 National Research Council Of Canada Process of raising squalene levels in plants and dna sequences used therefor
DK0888452T3 (en) * 1996-03-15 2004-06-14 Munin Corp Human CYR61, an extracellular matrix signaling molecule
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
TR199802421T2 (en) 1996-05-24 1999-02-22 Biogen , Inc. Substances that regulate tissue regeneration.
US5994526A (en) 1996-06-21 1999-11-30 Plant Genetic Systems Gene expression in plants
CA2255057A1 (en) 1996-06-21 1997-12-31 Plant Genetic Systems, N.V. Gene expression in plants
US5952546A (en) * 1996-06-27 1999-09-14 Dna Plant Technology Corporation Delayed ripening tomato plants with T-DNA bearing a truncated ACC2 synthase gene
US5850026A (en) 1996-07-03 1998-12-15 Cargill, Incorporated Canola oil having increased oleic acid and decreased linolenic acid content
JP2001503735A (en) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ Emulsion formulation for hydrophilic active reagent
IL128124A0 (en) * 1996-08-02 1999-11-30 Genesense Technologies Inc Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
DE19631919C2 (en) 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-sense RNA with secondary structure
US5747338A (en) 1996-08-15 1998-05-05 Chiron Corporation Method and construct for screening for inhibitors of transcriptional activation
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
GB9703146D0 (en) 1997-02-14 1997-04-02 Innes John Centre Innov Ltd Methods and means for gene silencing in transgenic plants
JP2001514491A (en) 1997-02-21 2001-09-11 ダニスコ エイ/エス Antisense intron inhibition of starch branching enzyme expression
CA2254785A1 (en) * 1997-03-10 1998-09-17 Japan Tobacco Inc. Antisense base sequences
GB9706381D0 (en) 1997-03-27 1997-05-14 Cambridge Advanced Tech Improvements relating to the specificity of gene expression
US7589253B2 (en) 1997-04-15 2009-09-15 Commonwealth Scientific And Industrial Research Organisation Fatty acid epoxygenase genes from plants and uses therefor in modifying fatty acid metabolism
US5942395A (en) 1997-05-09 1999-08-24 Universite De Montreal Hybrid ribozymes and methods of use
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
GB9720148D0 (en) 1997-09-22 1997-11-26 Innes John Centre Innov Ltd Gene silencing materials and methods
EP1032692A1 (en) 1997-11-18 2000-09-06 Pioneer Hi-Bred International, Inc. Targeted manipulation of herbicide-resistance genes in plants
DE19754622A1 (en) 1997-12-09 1999-06-10 Antje Von Dr Schaewen Plant GntI sequences and the use thereof for obtaining plants with reduced or missing N-acetylglucosaminyltransferase I (GnTI) activity
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
US8598332B1 (en) 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
EP1068311B2 (en) 1998-04-08 2020-12-09 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
EP0959133A1 (en) 1998-05-22 1999-11-24 Centrum Voor Plantenveredelings- En Reproduktieonderzoek (Cpro-Dlo) A process for inhibiting expression of genes
AR020078A1 (en) 1998-05-26 2002-04-10 Syngenta Participations Ag METHOD FOR CHANGING THE EXPRESSION OF AN OBJECTIVE GENE IN A PLANT CELL
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US6040908A (en) * 1998-07-28 2000-03-21 Litton Systems, Inc. Method for stress tuning fiber optic sensor coils
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
ES2316363T3 (en) 1999-04-20 2009-04-16 Bayer Bioscience N.V. METHODS FOR ADMINISTRATION OF RNA INHIBITOR TO THE PLANTS AND APPLICATIONS OF THE SAME.
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US20040138168A1 (en) 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
JP2003501102A (en) 1999-06-14 2003-01-14 エクセリクシス,インク Animal models and methods for the analysis of lipid metabolism and the screening of pharmaceuticals and insecticides that regulate lipid metabolism
IL147026A0 (en) 1999-07-09 2002-08-14 American Home Prod Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
AU7487300A (en) 1999-09-16 2001-04-17 Genoptera, Llc Lethal insectidice targets
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
GB9925459D0 (en) 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2047001A (en) 1999-11-24 2001-06-04 Dna Plant Technology Corporation Methods of inhibiting plant parasitic nematodes and insect pests by expression of nematode and insect specific double-stranded rna in plants
WO2001038359A2 (en) 1999-11-29 2001-05-31 Genoptera, Llc Drosophila nicotinic acetylcholine receptor
GB9930691D0 (en) 1999-12-24 2000-02-16 Devgen Nv Improvements relating to double-stranded RNA inhibition
CN1426466A (en) 2000-03-17 2003-06-25 贝尼泰克澳大利亚有限公司 Genetic silencing
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
GB2362383B (en) 2000-05-19 2003-12-31 Devgen Nv Gene expression system
US6995258B1 (en) * 2000-05-25 2006-02-07 City Of Hope Nucleolar targeting of therapeutics against HIV
HUP0302320A3 (en) 2000-06-23 2005-11-28 Pioneer Hi Bred Int Recombinant constructs and their use in reducing gene expression
US7109393B2 (en) 2000-08-15 2006-09-19 Mendel Biotechnology, Inc. Methods of gene silencing using inverted repeat sequences
ES2728168T3 (en) 2000-12-01 2019-10-22 Max Planck Gesellschaft Small RNA molecules that mediate RNA interference
US20020150968A1 (en) * 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
US7691995B2 (en) 2001-07-12 2010-04-06 University Of Massachusetts In vivo production of small interfering RNAS that mediate gene silencing
WO2003023015A2 (en) 2001-09-13 2003-03-20 California Institute Of Technology Method for expression of small antiviral rna molecules within a cell
JP2005502383A (en) 2001-09-27 2005-01-27 ティモシー アルバート ホルトン Method for preparing a nucleic acid library
US20030148519A1 (en) * 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US20040022748A1 (en) 2002-03-12 2004-02-05 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method of enhancing skin lightening
BR0308424A (en) 2002-03-14 2005-02-22 Commw Scient Ind Res Org Methods and means for efficiently downregulating the expression of any gene of interest in eukaryotic cells and organisms
ITRM20020253A1 (en) 2002-05-08 2003-11-10 Univ Roma SNRNA CHEMICAL MOLECULES WITH ANTISENSE SEQUENCES FOR SPLICING JUNCTIONS OF THE DYSTROPHINE GENE AND THERAPEUTIC APPLICATIONS.
US20040106566A1 (en) * 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
US20040234504A1 (en) * 2002-12-18 2004-11-25 Verma Inder M. Methods of inhibiting gene expression by RNA interference
ATE528402T1 (en) 2003-02-19 2011-10-15 Commw Scient Ind Res Org EFFICIENT GENE silencing in plants using short DSRNA sequences
US20080044906A1 (en) 2003-09-12 2008-02-21 Peter Michael Waterhouse Modified Gene-Silencing Nucleic Acid Molecules and Uses Thereof
CA2650861A1 (en) 2006-05-03 2007-11-15 Commonwealth Scientific And Industrial Research Organisation Improved gene silencing methods
US9642116B2 (en) * 2008-03-05 2017-05-02 Nxp B.V. Dynamic MBSFN area configuration method in consideration of radio resource efficiency and system thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102719454A (en) * 2012-06-15 2012-10-10 华南农业大学 Optimized sulfide quinine oxidation-reduction enzyme gene and expression vector thereof
CN102719454B (en) * 2012-06-15 2014-07-30 华南农业大学 Optimized sulfide quinine oxidation-reduction enzyme gene and expression vector thereof

Also Published As

Publication number Publication date
EP1624060B1 (en) 2011-09-28
KR101054060B1 (en) 2011-08-04
GB2353282C (en) 2013-02-27
US20040237145A1 (en) 2004-11-25
BR9908967A (en) 2000-12-19
EP1071762A1 (en) 2001-01-31
AU2005202658B2 (en) 2008-08-21
SK13722000A3 (en) 2001-05-10
EP1857549A2 (en) 2007-11-21
EP1624060A2 (en) 2006-02-08
ES2374290T3 (en) 2012-02-15
NZ506648A (en) 2003-08-29
AU2005211538B2 (en) 2008-07-24
EP1857549A3 (en) 2007-12-05
ATE526405T1 (en) 2011-10-15
JP2009219504A (en) 2009-10-01
ES2374534T3 (en) 2012-02-17
EP1555317B1 (en) 2011-09-28
SG141233A1 (en) 2008-04-28
AU3564702A (en) 2002-06-13
HK1035742A1 (en) 2001-12-07
KR20010042069A (en) 2001-05-25
SK287538B6 (en) 2011-01-04
NZ547283A (en) 2008-06-30
HUP0101225A1 (en) 2001-08-28
AU2005209648B2 (en) 2008-08-21
EP2302057A1 (en) 2011-03-30
GB2353282A (en) 2001-02-21
ATE526406T1 (en) 2011-10-15
GB2353282A8 (en) 2008-06-23
CA2323726A1 (en) 1999-09-30
AU2005202658A1 (en) 2005-07-14
EP1071762A4 (en) 2003-09-24
AU2008249157A1 (en) 2008-12-11
KR101085210B1 (en) 2011-11-21
AU743316B2 (en) 2002-01-24
KR20100039457A (en) 2010-04-15
AU2005209648A1 (en) 2005-10-06
AU2916399A (en) 1999-10-18
JP4187413B2 (en) 2008-11-26
WO1999049029A1 (en) 1999-09-30
EP2302057B1 (en) 2019-02-20
AU2005211538A1 (en) 2005-10-13
CZ20003346A3 (en) 2001-03-14
EP1857549B1 (en) 2018-10-17
BRPI9908967B1 (en) 2017-05-30
JP4187737B2 (en) 2008-11-26
ZA200004507B (en) 2001-12-24
US20030074684A1 (en) 2003-04-17
CA2323726C (en) 2005-02-08
AU2008249157B2 (en) 2011-03-03
EP1624060A3 (en) 2006-04-26
US20120277285A1 (en) 2012-11-01
HUP0101225A3 (en) 2004-08-30
US20040064842A1 (en) 2004-04-01
JP2002507416A (en) 2002-03-12
CN1294631A (en) 2001-05-09
US20140193856A1 (en) 2014-07-10
AU2005211538C1 (en) 2014-02-13
JP2008073055A (en) 2008-04-03
PL343064A1 (en) 2001-07-30
JP4981103B2 (en) 2012-07-18
CA2487328A1 (en) 1999-09-30
KR20060030526A (en) 2006-04-10
US7754697B2 (en) 2010-07-13
US9963698B2 (en) 2018-05-08
JP2005323615A (en) 2005-11-24
CZ295108B6 (en) 2005-05-18
GB0024727D0 (en) 2000-11-22
CN101818145A (en) 2010-09-01
SG115493A1 (en) 2005-10-28
US8168774B2 (en) 2012-05-01
CN1796556A (en) 2006-07-05
HU230353B1 (en) 2016-02-29
EP1555317A1 (en) 2005-07-20
US20060014715A1 (en) 2006-01-19
AU743316C (en) 2005-09-15
JP4460600B2 (en) 2010-05-12
GB2353282B (en) 2003-06-04
DK1624060T3 (en) 2012-04-10

Similar Documents

Publication Publication Date Title
CA2323726C (en) Control of gene expression
MXPA00008631A (en) Control of gene expression

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued